

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT7444440

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
ALEXION PHARMACEUTICALS, INC.	12/02/2020
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	ALEXION PHARMA INTERNATIONAL OPERATIONS UNLIMITED COMPANY
<b>Street Address:</b>	COLLEGE BUSINESS & TECHNOLOGY PARK
<b>City:</b>	BLANCHARDSTOWN, DUBLIN 15
<b>State/Country:</b>	IRELAND
<b>PROPERTY NUMBERS Total: 6</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	17196197
Application Number:	17569402
Application Number:	17176939
Application Number:	17334427
Application Number:	17698718
Application Number:	17196172
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Email:</b>	patents@alexion.com
<b>Correspondent Name:</b>	ALEXION PHARMACEUTICALS, INC.
<b>Address Line 1:</b>	100 COLLEGE STREET
<b>Address Line 4:</b>	NEW HAVEN, CONNECTICUT 06510
<b>ATTORNEY DOCKET NUMBER:</b>	ANDEXANET
<b>NAME OF SUBMITTER:</b>	TRACIE CROTHERS
<b>SIGNATURE:</b>	/Tracie Crothers/
<b>DATE SIGNED:</b>	07/21/2022
<b>Total Attachments: 79</b>	
source=3_API to APIOU Executed Assignment with Schedule - Copy#page1.tif	
source=3_API to APIOU Executed Assignment with Schedule - Copy#page2.tif	



source=3\_API to APIOU Executed Assignment with Schedule - Copy#page51.tif  
source=3\_API to APIOU Executed Assignment with Schedule - Copy#page52.tif  
source=3\_API to APIOU Executed Assignment with Schedule - Copy#page53.tif  
source=3\_API to APIOU Executed Assignment with Schedule - Copy#page54.tif  
source=3\_API to APIOU Executed Assignment with Schedule - Copy#page55.tif  
source=3\_API to APIOU Executed Assignment with Schedule - Copy#page56.tif  
source=3\_API to APIOU Executed Assignment with Schedule - Copy#page57.tif  
source=3\_API to APIOU Executed Assignment with Schedule - Copy#page58.tif  
source=3\_API to APIOU Executed Assignment with Schedule - Copy#page59.tif  
source=3\_API to APIOU Executed Assignment with Schedule - Copy#page60.tif  
source=3\_API to APIOU Executed Assignment with Schedule - Copy#page61.tif  
source=3\_API to APIOU Executed Assignment with Schedule - Copy#page62.tif  
source=3\_API to APIOU Executed Assignment with Schedule - Copy#page63.tif  
source=3\_API to APIOU Executed Assignment with Schedule - Copy#page64.tif  
source=3\_API to APIOU Executed Assignment with Schedule - Copy#page65.tif  
source=3\_API to APIOU Executed Assignment with Schedule - Copy#page66.tif  
source=3\_API to APIOU Executed Assignment with Schedule - Copy#page67.tif  
source=3\_API to APIOU Executed Assignment with Schedule - Copy#page68.tif  
source=3\_API to APIOU Executed Assignment with Schedule - Copy#page69.tif  
source=3\_API to APIOU Executed Assignment with Schedule - Copy#page70.tif  
source=3\_API to APIOU Executed Assignment with Schedule - Copy#page71.tif  
source=3\_API to APIOU Executed Assignment with Schedule - Copy#page72.tif  
source=3\_API to APIOU Executed Assignment with Schedule - Copy#page73.tif  
source=3\_API to APIOU Executed Assignment with Schedule - Copy#page74.tif  
source=3\_API to APIOU Executed Assignment with Schedule - Copy#page75.tif  
source=3\_API to APIOU Executed Assignment with Schedule - Copy#page76.tif  
source=3\_API to APIOU Executed Assignment with Schedule - Copy#page77.tif  
source=3\_API to APIOU Executed Assignment with Schedule - Copy#page78.tif  
source=3\_API to APIOU Executed Assignment with Schedule - Copy#page79.tif

## WORLD-WIDE ASSIGNMENT

This assignment, effective on October 30, 2020, is between

ALEXION PHARMACEUTICALS, INC., a Delaware corporation having a place of business at 121 Seaport Boulevard, Boston, Massachusetts 02210 (hereinafter "ASSIGNOR"), and


ALEXION PHARMA INTERNATIONAL OPERATIONS UNLIMITED COMPANY, an Irish unlimited company having a place of business at College Business & Technology Park, Blanchardstown, Dublin 15, Ireland (hereinafter "ASSIGNEE").

WHEREAS, ASSIGNOR owns the entire right, title, interest and intellectual property rights, including rights of priority, arising under or pursuant to any and all international agreements, treaties or laws relating to the protection of industrial property, in and throughout the world, including the United States of America and its territories, for inventions and improvements, to said patents and applications listed on Schedule A and to such letters patents as may or shall issue on said inventions, or any parts thereof, or any divisional, continuing, reissue or other application(s) based in whole or in part thereon said inventions, applications, and letters patents (hereinafter "PATENT RIGHTS"), and ASSIGNOR wishes to convey and transfer all of its right, title, interest and intellectual property rights in and to said PATENT RIGHTS to ASSIGNEE.

NOW, THEREFORE, for good and valuable consideration paid by ASSIGNEE to ASSIGNOR, the receipt and sufficiency of which are hereby acknowledged, ASSIGNOR hereby assigns, and confirms assignment, to ASSIGNEE, its successors and assignees, absolutely, its entire right, title, interest and intellectual property rights in and to the PATENT RIGHTS, including the right to sue for past infringement thereof.

ASSIGNOR hereby acknowledges that this assignment, being of the entire right, title and interest in and to said PATENT RIGHTS, carries with it the right in ASSIGNEE to apply for and obtain from competent authorities in all countries of the world any and all letters patent by attorneys and agents of ASSIGNEE's selection and the right to procure the grant of all such letters patent to ASSIGNEE for its own name and assignee of the entire right, title and interest therein.


IN TESTIMONY WHEREOF, ASSIGNOR has caused this assignment to be executed by its duly authorized officer.

  
By: Todd Spalding  
Title: SVP and Head of Intellectual Property  
ALEXION PHARMACEUTICALS, INC.


Date: December 2, 2020

United States of America )  
State of Massachusetts ) ss.:  
County of Middlesex )

On this 2 day of December, 2020 before me, the  
undersigned notary public, personally appeared Todd Spalding  
(name of document signer), proved to me through satisfactory evidence of identification,  
which was MA DRIVER'S LICENSE, to be the person whose name  
is signed on the preceding or attached document in my presence.

  
\_\_\_\_\_  
(official signature and seal of notary)

My commission expires 12/31/2022



ASSIGNEE:

I hereby acknowledge that rights in the above-identified application have transferred from the assignor by virtue of its above execution of this assignment and are hereby conveyed to Alexion Pharma International Operations Unlimited Company, the ASSIGNEE, of which I am an authorized signatory.

*Michael Ellison*

By: Michael Ellison  
Title: Director  
ALEXION PHARMA INTERNATIONAL  
OPERATIONS UNLIMITED COMPANY

Date: December 3, 2020

Date: December 3, 2020

United States of America )  
State of Connecticut ) ss:  
County of New Haven )

On this 3rd day of December, 2020 before me, the  
the undersigned notary public, personally appeared Michael Ellison  
(name of document signer), proved to me through satisfactory evidence of identification,  
which was CT Driver's License, to be the person whose name  
is signed on the preceding or attached document in my presence.

*Nicole L. Fossum* (official signature and seal of notary)

My commission expires February 28, 2025

Nicole L. Fossum  
Notary Public-Connecticut  
My Commission Expires  
February 28, 2025

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0821 US P1	PTL001200US	UNITED STATES	PLATELET ADP RECEPTOR INHIBITORS	60/180,208	2/4 /2000		
0821 US P2	PTL001201US	UNITED STATES	PLATELET ADP RECEPTOR INHIBITORS	60/202,072	5/5 /2000		
0821 US P3	PTL001202US	UNITED STATES	PLATELET ADP RECEPTOR INHIBITORS	60/230,447	9/6 /2000		
0821 AT	PTL001210AT	AUSTRIA	PLATELET ADP RECEPTOR INHIBITORS	019088178	2/5 /2001	1257550	11/16/2005
0821 AU	PTL001210AU	AUSTRALIA	PLATELET ADP RECEPTOR INHIBITORS	2001236644	2/5 /2001	2001236644	9/14/2006
0821 BE	PTL001210BE	BELGIUM	PLATELET ADP RECEPTOR INHIBITORS	019088178	2/5 /2001	1257550	11/16/2005
0821 CA	PTL001210CA	CANADA	PLATELET ADP RECEPTOR INHIBITORS	2400479	2/5 /2001	2400479	10/5 /2010
0821 CH	PTL001210CH	SWITZERLAND	PLATELET ADP RECEPTOR INHIBITORS	019088178	2/5 /2001	1257550	11/16/2005
0821 DE	PTL001210DE	GERMANY	PLATELET ADP RECEPTOR INHIBITORS	019088178	2/5 /2001	60114994-7 T2	11/16/2005
0821 DK	PTL001210DK	DENMARK	INHIBITORS	019088178	2/5 /2001	1257550	11/16/2005
0821 EP	PTL001210EP	EUROPEAN PATENT CONVENT	PLATELET ADP RECEPTOR INHIBITORS	019088178	2/5 /2001	1257550	11/16/2005
0821 ES	PTL001210ES	SPAIN	PLATELET ADP RECEPTOR INHIBITORS	019088178	2/5 /2001	1257550	11/16/2005
0821 FI	PTL001210FI	FINLAND	INHIBITORS	019088178	2/5 /2001	1257550	11/16/2005
0821 FR	PTL001210FR	FRANCE	PLATELET ADP RECEPTOR INHIBITORS	019088178	2/5 /2001	1257550	11/16/2005
0821 GB	PTL001210GB	UNITED KINGDOM	PLATELET ADP RECEPTOR INHIBITORS	019088178	2/5 /2001	1257550	11/16/2005
0821 GR	PTL001210GR	GREECE	PLATELET ADP RECEPTOR INHIBITORS	019088178	2/5 /2001	1257550	11/16/2005
0821 IE	PTL001210IE	IRELAND	INHIBITORS	019088178	2/5 /2001	1257550	11/16/2005
0821 IT	PTL001210IT	ITALY	PLATELET ADP RECEPTOR INHIBITORS	019088178	2/5 /2001	5022006901385202	11/16/2005
0821 JP	PTL001210JP	JAPAN	INHIBITORS	2001-557869	2/5 /2001	4574100	8 /27/2010
0821 MC	PTL001210MC	MONACO	PLATELET ADP RECEPTOR INHIBITORS	019088178	2/5 /2001	1257550	11/16/2005
0821 NL	PTL001210NL	NETHERLANDS	INHIBITORS	019088178	2/5 /2001	1257550	11/16/2005
0821 WO	PTL001210PC	WIPO	PLATELET ADP RECEPTOR INHIBITORS	PCT/US01/03585	2/5 /2001		
0821 PT	PTL001210PT	PORTUGAL	PLATELET ADP RECEPTOR INHIBITORS	019088178	2/5 /2001	1257550	11/16/2005

PATENT

REEL: 060800 FRAME: 0245

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0821 SE	PTL001210SE	SWEDEN	PLATELET ADP RECEPTOR INHIBITORS	01908817.8	2/5/2001	1257550	11/16/2005
0821 TR	PTL001210TR	TURKEY	PLATELET ADP RECEPTOR INHIBITORS	01908817.8	2/5/2001	2006 00602	11/16/2005
0821 US	PTL001210US	UNITED STATES	PLATELET ADP RECEPTOR INHIBITORS	09/775.812	2/5/2001		
0821 JP D1	PTL001211JP	JAPAN	PLATELET ADP RECEPTOR INHIBITORS	2010-076419	2/5/2001		
0821 US C1	PTL001211US	UNITED STATES	PLATELET ADP RECEPTOR INHIBITORS	10/350.883	1/23/2003	6,689,786	2/10/2004
0821 US C2	PTL001212US	UNITED STATES	PLATELET ADP RECEPTOR INHIBITORS	10/759.396	1/15/2004	7,022,731	4/4/2006
0821 US C3	PTL001213US	UNITED STATES	PLATELET ADP RECEPTOR INHIBITORS	11/286.259	11/23/2005	7,678,790	3/16/2010
0821 US C4	PTL001214US	UNITED STATES	PLATELET ADP RECEPTOR INHIBITORS	12/642.379	12/18/2009		
0821 CA X1	PTL001220CA	CANADA	PLATELET ADP RECEPTOR INHIBITORS	2468925	7/25/2002		
0821 DE X1	PTL001220DE	GERMANY	PLATELET ADP RECEPTOR INHIBITORS	02750339.0	7/25/2002	60214730.1-08	9/13/2006
0821 EP X1	PTL001220EP	EUROPEAN PATENT CONVENT	PLATELET ADP RECEPTOR INHIBITORS	02750339.0	7/25/2002	1412364	9/13/2006
0821 ES X1	PTL001220ES	SPAIN	PLATELET ADP RECEPTOR INHIBITORS	02750339.0	7/25/2002	1412364	9/13/2006
0821 FR X1	PTL001220FR	FRANCE	PLATELET ADP RECEPTOR INHIBITORS	02750339.0	7/25/2002	1412364	9/13/2006
0821 GB X1	PTL001220GB	UNITED KINGDOM	PLATELET ADP RECEPTOR INHIBITORS	02750339.0	7/25/2002	1412364	9/13/2006
0821 HK X1	PTL001220HK	HONG KONG	PLATELET ADP RECEPTOR INHIBITORS	04106901.1	7/25/2002	1064099	5/25/2007
0821 IT X1	PTL001220IT	ITALY	PLATELET ADP RECEPTOR INHIBITORS	02750339.0	7/25/2002	1412364	9/13/2006
0821 JP X1	PTL001220JP	JAPAN	PLATELET ADP RECEPTOR INHIBITORS	2003-517063	7/25/2002	4648626	12/17/2010
0821 WO X1	PTL001220PC	WIPO	PLATELET ADP RECEPTOR INHIBITORS	PCT/US2002/023909	7/25/2002		
0821 US X1	PTL001220US	UNITED STATES	PLATELET ADP RECEPTOR INHIBITORS	09/920.325	8/12/2001	6,906,063	6/14/2005
0821 AT X1D1	PTL001221AT	AUSTRIA	PLATELET ADP RECEPTOR INHIBITORS	06015189.1	7/25/2002	1734041	10/20/2010
0821 BE X1D1	PTL001221BE	BELGIUM	PLATELET ADP RECEPTOR INHIBITORS	06015189.1	7/25/2002	1734041	10/20/2010
0821 BG X1D1	PTL001221BG	BULGARIA	PLATELET ADP RECEPTOR INHIBITORS	06015189.1	7/25/2002	1734041	10/20/2010
0821 CH X1D1	PTL001221CH	SWITZERLAND	PLATELET ADP RECEPTOR INHIBITORS	06015189.1	7/25/2002	1734041	10/20/2010

PATENT

REEL: 060800 FRAME: 0246



SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0821 CY X1D1	PTL001221CY	CYPRUS	PLATELET ADP RECEPTOR INHIBITORS	06015189.1	7/25/2002	1734041 (CV1112024)	10/20/2010
0821 CZ X1D1	PTL001221CZ	CZECH REPUBLIC	PLATELET ADP RECEPTOR INHIBITORS	06015189.1	7/25/2002	1734041	10/20/2010
0821 DE X1D1	PTL001221DE	GERMANY	PLATELET ADP RECEPTOR INHIBITORS	06015189.1	7/25/2002	60238086.3-08	10/20/2010
0821 DK X1D1	PTL001221DK	DENMARK	PLATELET ADP RECEPTOR INHIBITORS	06015189.1	7/25/2002	1734041	10/20/2010
0821 EE X1D1	PTL001221EE	ESTONIA	PLATELET ADP RECEPTOR INHIBITORS	06015189.1	7/25/2002	1734041	10/20/2010
0821 EP X1D1	PTL001221EP	EUROPEAN PATENT CONVENT	PLATELET ADP RECEPTOR INHIBITORS	06015189.1	7/25/2002	1734041	10/20/2010
0821 ES X1D1	PTL001221ES	SPAIN	PLATELET ADP RECEPTOR INHIBITORS	06015189.1	7/25/2002	1734041	10/20/2010
0821 FI X1D1	PTL001221FI	FINLAND	PLATELET ADP RECEPTOR INHIBITORS	06015189.1	7/25/2002	1734041	10/20/2010
0821 FR X1D1	PTL001221FR	FRANCE	PLATELET ADP RECEPTOR INHIBITORS	06015189.1	7/25/2002	1734041	10/20/2010
0821 GB X1D1	PTL001221GB	UNITED KINGDOM	PLATELET ADP RECEPTOR INHIBITORS	06015189.1	7/25/2002	1734041	10/20/2010
0821 GR X1D1	PTL001221GR	GREECE	PLATELET ADP RECEPTOR INHIBITORS	06015189.1	7/25/2002	1734041	10/20/2010
0821 HK X1D1	PTL001221HK	HONG KONG	PLATELET ADP RECEPTOR INHIBITORS	07102667.1	7/25/2002	1096088	5/13/2011
0821 IE X1D1	PTL001221IE	IRELAND	PLATELET ADP RECEPTOR INHIBITORS	06015189.1	7/25/2002	1734041	10/20/2010
0821 IT X1D1	PTL001221IT	ITALY	PLATELET ADP RECEPTOR INHIBITORS	06015189.1	7/25/2002	502011901906411	10/20/2010
0821 JP X1D1	PTL001221JP	JAPAN	PLATELET ADP RECEPTOR INHIBITORS	2010-76428	7/25/2002		
0821 LU X1D1	PTL001221LU	LUXEMBOURG	PLATELET ADP RECEPTOR INHIBITORS	06015189.1	7/25/2002	1734041	10/20/2010
0821 NL X1D1	PTL001221NL	NETHERLANDS	PLATELET ADP RECEPTOR INHIBITORS	06015189.1	7/25/2002	1734041	10/20/2010
0821 PT X1D1	PTL001221PT	PORTUGAL	PLATELET ADP RECEPTOR INHIBITORS	06015189.1	7/25/2002	1734041	10/20/2010
0821 SE X1D1	PTL001221SE	SWEDEN	PLATELET ADP RECEPTOR INHIBITORS	06015189.1	7/25/2002	1734041	10/20/2010
0821 SK X1D1	PTL001221SK	SLOVAK REPUBLIC	PLATELET ADP RECEPTOR INHIBITORS	06015189.1	7/25/2002	1734041	10/20/2010
0821 TR X1D1	PTL001221TR	TURKEY	PLATELET ADP RECEPTOR INHIBITORS	06015189.1	7/25/2002	2011 00456	10/20/2010
0821 US X1C1	PTL001221US	UNITED STATES	PLATELET ADP RECEPTOR INHIBITORS	10/941,053	9/13/2004	7,056,926	6/6/2006
0821 CH X1D2	PTL001222CH	SWITZERLAND	PLATELET ADP RECEPTOR INHIBITORS	10183633.6	7/25/2002	2314593	5/4/2016

PATENT

REEL: 060800 FRAME: 0247

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0821 DE X1D2	PTL001222DE	GERMANY	PLATELET ADP RECEPTOR INHIBITORS	10183633.6	7/25/2002	60248053-1 (2314593)	5/4/2016
0821 EP X1D2	PTL001222EP	EUROPEAN PATENT CONVENT	PLATELET ADP RECEPTOR INHIBITORS	10183633.6	7/25/2002	2314593	5/4/2016
0821 FR X1D2	PTL001222FR	FRANCE	PLATELET ADP RECEPTOR INHIBITORS	10183633.6	7/25/2002	2314593	5/4/2016
0821 GB X1D2	PTL001222GB	UNITED KINGDOM	PLATELET ADP RECEPTOR INHIBITORS	10183633.6	7/25/2002	2314593	5/4/2016
0821 HK X1D2	PTL001222HK	HONG KONG	PLATELET ADP RECEPTOR INHIBITORS	11111603.3	7/25/2002	1157331	11/18/2016
0821 IE X1D2	PTL001222IE	IRELAND	PLATELET ADP RECEPTOR INHIBITORS	10183633.6	7/25/2002	2314593	5/4/2016
0821 US X1C2	PTL001222US	UNITED STATES	PLATELET ADP RECEPTOR INHIBITORS	111293.026	12/1/2005	7.358.257	4/15/2008
0821 US X1C3	PTL001223US	UNITED STATES	PLATELET ADP RECEPTOR INHIBITORS	11/841.711	8/20/2007	7.622.474	11/24/2009
0821 US X1C4	PTL001224US	UNITED STATES	PLATELET ADP RECEPTOR INHIBITORS	12/559.389	9/14/2009	8.067.428	11/29/2011
0821 US X1C5	PTL001225US	UNITED STATES	PLATELET ADP RECEPTOR INHIBITORS	13/270.193	10/10/2011	8.524.721	9/3/2013
0821 US X1C6	PTL001226US	UNITED STATES	PLATELET ADP RECEPTOR INHIBITORS	13/956.251	7/31/2013		
0823 US P1	PTL001300US	UNITED STATES	BENZOFUSED PLATELET ADP RECEPTOR INHIBITORS	60/202.075	5/5/2000		
0823 US P2	PTL001301US	UNITED STATES	BENZOFUSED PLATELET ADP RECEPTOR INHIBITORS	60/230.456	9/6/2000		
0823 AU	PTL001310AU	AUSTRALIA	HETEROBICYCLIC SULFONAMIDES AND THEIR USE AS PLATELET ADP RECEPTOR INHIBITORS	2001264566	5/4/2001		
0823 CA	PTL001310CA	CANADA	HETEROBICYCLIC SULFONAMIDES AND THEIR USE AS PLATELET ADP RECEPTOR INHIBITORS	2408156	5/4/2001		
0823 EP	PTL001310EP	EUROPEAN PATENT CONVENT	HETEROBICYCLIC SULFONAMIDES AND THEIR USE AS PLATELET ADP RECEPTOR INHIBITORS	01938998.0	5/4/2001		
0823 JP	PTL001310JP	JAPAN	HETEROBICYCLIC SULFONAMIDES AND THEIR USE AS PLATELET ADP RECEPTOR INHIBITORS	2001-582323	5/4/2001		
0823 WO	PTL001310PC	WIPO	HETEROBICYCLIC SULFONAMIDES AND THEIR USE AS PLATELET ADP RECEPTOR INHIBITORS	PCT/US2001/014441	5/4/2001		

PATENT

REEL: 060800 FRAME: 0248

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTFOLIA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0823 US	PTL001310US	UNITED STATES	HETEROBICYCLIC SULFONAMIDES AND THEIR USE AS PLATELET ADP RECEPTOR INHIBITORS	10/275,154	11/1/2002		
0824 US P2	PTL001401US	UNITED STATES	BICYCLIC FUSED HETEROBICYCLIC PLATELET ADP RECEPTOR INHIBITORS	60/317,192	9/6/2001		
0824 WO	PTL001410PC	WIPO	PIPERAZINE AND HOMOPIPERAZINE COMPOUNDS	PCT/US2002/028618	9/6/2002		
0824 US	PTL001410US	UNITED STATES	4-THIENYL-2,3-DIPYRIMIDIN-4-YL PIPERAZINE COMPOUNDS	10/237,153	9/6/2002	7,115,741	10/3/2006
0825 US P1	PTL001500US	UNITED STATES	2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS	60/508,564	10/3/2003		
0825 AT	PTL001510AT	AUSTRIA	2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS	04789522.2	9/29/2004	<del>E448222/</del> EP1668002	11/1/2009
0825 AU	PTL001510AU	AUSTRALIA	2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS	2004278030	9/29/2004	2004278030	11/29/2010
0825 BE	PTL001510BE	BELGIUM	2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS	04789522.2	9/29/2004	1668002	11/1/2009
0825 CA	PTL001510CA	CANADA	2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS	2540214	9/29/2004		
0825 CH	PTL001510CH	SWITZERLAND	2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS	04789522.2	9/29/2004	1668002	11/1/2009
0825 CN	PTL001510CN	CHINA	2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS	200480028791.3	9/29/2004	ZL200480028791.3	8/31/2011
0825 DE	PTL001510DE	GERMANY	2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS	04789522.2	9/29/2004	602004024093.1-08	11/1/2009
0825 EP	PTL001510EP	EUROPEAN PATENT CONVENT	2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS	04789522.2	9/29/2004	1668002	
0825 ES	PTL001510ES	SPAIN	2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS	04789522.2	9/29/2004	1668002	11/1/2009
0825 FR	PTL001510FR	FRANCE	2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS	04789522.2	9/29/2004	1668002	11/1/2009
0825 GB	PTL001510GB	UNITED KINGDOM	2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS	04789522.2	9/29/2004	1668002	11/1/2009
0825 GR	PTL001510GR	GREECE	2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS	04789522.2	9/29/2004	1668002	11/1/2009
0825 HK	PTL001510HK	HONG KONG	2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS	06113688.4	9/29/2004	1093973	8/16/2010
0825 IL	PTL001510IL	ISRAEL	2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS	174446	9/29/2004	174446	5/30/2012
0825 IN	PTL001510IN	INDIA	2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS	828/KOLNP/2006	9/29/2004	246198	2/21/2011
0825 IT	PTL001510IT	ITALY	2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS	04789522.2	9/29/2004	1668002	11/1/2009
0825 JP	PTL001510JP	JAPAN	2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS	2006-5344290	9/29/2004		

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0825 KR	PTL001510KR	SOUTH KOREA	2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS	10-2006-7008644	9/29/2004		
0825 MX	PTL001510MX	MEXICO	2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS	Pa/a/2006/003618	9/29/2004	277000	6/30/2010
0825 NL	PTL001510NL	NETHERLANDS	2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS	04789522.2	9/29/2004	1668002	11/11/2009
0825 WO	PTL001510PC	WIPO	2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS	PCT/US2004/032921	9/29/2004		
0825 PL	PTL001510PL	POLAND	2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS	04789522.2	9/29/2004	1668002	11/11/2009
0825 PT	PTL001510PT	PORTUGAL	2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS	04789522.2	9/29/2004	1668002	11/11/2009
0825 SG	PTL001510SG	SINGAPORE	2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS	200602046-5	9/29/2004	120755	2/27/2009
0825 TR	PTL001510TR	TURKEY	2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS	04789522.2	9/29/2004	1668002	11/11/2009
0825 US	PTL001510US	UNITED STATES	2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS	10/956.004	9/29/2004	7,109,332	9/19/2006
0826 US P1	PTL001600US	UNITED STATES	SUBSTITUTED ISOQUINOLINONES	60/508,402	10/3/2003		
0826 AU	PTL001610AU	AUSTRALIA	SUBSTITUTED ISOQUINOLINONES	2004279809	9/29/2004	2004279809	10/28/2010
0826 CA	PTL001610CA	CANADA	SUBSTITUTED ISOQUINOLINONES	2539882	9/29/2004		
0826 CN	PTL001610CN	CHINA	SUBSTITUTED ISOQUINOLINONES	200480028944.4	9/29/2004	ZL200480028944.4	6/9/2010
0826 EP	PTL001610EP	EUROPEAN PATENT CONVENT	SUBSTITUTED ISOQUINOLINONES	04785303.1	9/29/2004		
0826 HK	PTL001610HK	HONG KONG	SUBSTITUTED ISOQUINOLINONES	06113687.5	9/29/2004		
0826 IL	PTL001610IL	ISRAEL	SUBSTITUTED ISOQUINOLINONES	174445	9/29/2004	174445	5/30/2012
0826 IN	PTL001610IN	INDIA	SUBSTITUTED ISOQUINOLINONES	829/KOLNP/2006	9/29/2004	247498	4/12/2011
0826 JP	PTL001610JP	JAPAN	SUBSTITUTED ISOQUINOLINONES	2006-534084	9/29/2004	4879745	12/9/2011
0826 KR	PTL001610KR	SOUTH KOREA	SUBSTITUTED ISOQUINOLINONES	10-2006-7008642	9/29/2004		
0826 MX	PTL001610MX	MEXICO	SUBSTITUTED ISOQUINOLINONES	Pa/a/2006/003625	9/29/2004	258231	6/25/2008
0826 WO	PTL001610PC	WIPO	SUBSTITUTED ISOQUINOLINONES	PCT/US2004/032104	9/29/2004		
0826 SG	PTL001610SG	SINGAPORE	SUBSTITUTED ISOQUINOLINONES	200602045-7	9/29/2004	120754	3/31/2009
0826 US P1	PTL001610US	UNITED STATES	SUBSTITUTED ISOQUINOLINONES	10/956.006	9/29/2004	7,294,635	11/13/2007

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTFOLIA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0827 US P1	PTL001700US	UNITED STATES	NOVEL ADP RECEPTOR	60/171,622	12/23/1999		
0827 EP	PTL001710EP	EUROPEAN PATENT	P2Y12 RECEPTOR METHODS OF IDENTIFYING AGENTS THAT MODULATE P2Y12 RECEPTOR ACTIVITY	00986695.5	12/26/2000		
0827 US	PTL001710US	UNITED STATES	DEVICE AND METHODS FOR IDENTIFYING AND TREATING ASPIRIN NON-RESPONSIVE PATIENTS	09/745,842	12/26/2000	6,762,029	7/13/2004
0828 US P1	PTL001800US	UNITED STATES	DEVICE AND METHODS FOR IDENTIFYING AND TREATING ASPIRIN NON-RESPONSIVE PATIENTS	60/559,120	4/1/2004		
0828 US P2	PTL001801US	UNITED STATES	DEVICE AND METHODS FOR IDENTIFYING AND TREATING ASPIRIN NON-RESPONSIVE PATIENTS	60/636,744	12/14/2004		
0828 WO	PTL001810PC	WIPO	DEVICE AND METHODS FOR IDENTIFYING AND TREATING ASPIRIN NON-RESPONSIVE PATIENTS	PCT/US2005/045445	12/14/2005		
0828 US	PTL001810US	UNITED STATES	DEVICE AND METHODS FOR IDENTIFYING AND TREATING ASPIRIN NON-RESPONSIVE PATIENTS	11/304,054	12/14/2005	7,356,091	4/15/2008
0828 US D1	PTL001811US	UNITED STATES	DEVICE AND METHODS FOR IDENTIFYING AND TREATING ASPIRIN NON-RESPONSIVE PATIENTS	12/037,012	2/25/2008	7,786,891	8/31/2010
0831 P1	PTL002100US	UNITED STATES	SUBSTITUTED 2H-1,3-BENZOXAZIN-4(3H)-ONES	60/614,564	9/29/2004		
0831 AU	PTL002110AU	AUSTRALIA	SUBSTITUTED 2H-1,3-BENZOXAZIN-4(3H)-ONES	2005292314	9/26/2005	2005292314	2/16/2012
0831 BR	PTL002110BR	BRAZIL	SUBSTITUTED 2H-1,3-BENZOXAZIN-4(3H)-ONES	P10516181-9	9/26/2005		
0831 CA	PTL002110CA	CANADA	SUBSTITUTED 2H-1,3-BENZOXAZIN-4(3H)-ONES	2581638	9/26/2005		
0831 CN	PTL002110CN	CHINA	SUBSTITUTED 2H-1,3-BENZOXAZIN-4(3H)-ONES	200580032884.8	9/26/2005	ZL200580032884.8	9/29/2010
0831 EP	PTL002110EP	EUROPEAN PATENT	SUBSTITUTED 2H-1,3-BENZOXAZIN-4(3H)-ONES	05798632.5	9/26/2005		
0831 HK	PTL002110HK	HONG KONG	SUBSTITUTED 2H-1,3-BENZOXAZIN-4(3H)-ONES	08102004.2	9/26/2005		
0831 IL	PTL002110IL	ISRAEL	SUBSTITUTED 2H-1,3-BENZOXAZIN-4(3H)-ONES	182180	9/26/2005		
0831 IN	PTL002110IN	INDIA	SUBSTITUTED 2H-1,3-BENZOXAZIN-4(3H)-ONES	1375/KOLNP/2007	9/26/2005		
0831 JP	PTL002110JP	JAPAN	SUBSTITUTED 2H-1,3-BENZOXAZIN-4(3H)-ONES	2007-534673	9/26/2005		

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0831 KR	PTL002110KR	SOUTH KOREA	SUBSTITUTED 2H-1,3-BENZOXAZIN-4(3H)-ONES	10-2007-7009902	9/126/2005		
0831 MX	PTL002110MX	MEXICO	SUBSTITUTED 2H-1,3-BENZOXAZIN-4(3H)-ONES	MX/a/2007/003836	9/126/2005	263047	12/10/2008
0831 NZ	PTL002110NZ	NEW ZEALAND	SUBSTITUTED 2H-1,3-BENZOXAZIN-4(3H)-ONES	554211	9/126/2005	554211	2/9/2011
0831 WO	PTL002110PC	WIPO	SUBSTITUTED 2H-1,3-BENZOXAZIN-4(3H)-ONES	PCT/US2005/034246	9/126/2005		
0831 SG	PTL002110SG	SINGAPORE	SUBSTITUTED 2H-1,3-BENZOXAZIN-4(3H)-ONES	200702187-6	9/126/2005	131244	12/31/2009
0831 US	PTL002110US	UNITED STATES	SUBSTITUTED 2H-1,3-BENZOXAZIN-4(3H)-ONES	11/236,051	9/126/2005	7,205,296	4/17/2007
0831 ZA	PTL002110ZA	SOUTH AFRICA	SUBSTITUTED 2H-1,3-BENZOXAZIN-4(3H)-ONES	2007/02688	9/126/2005	2007/02688	6/125/2008
0831 US C1	PTL002111US	UNITED STATES	SUBSTITUTED 2H-1,3-BENZOXAZIN-4(3H)-ONES	11/685,498	3/13/2007		
0832 US P1	PTL002200US	UNITED STATES	UREAS AS FACTOR YA INHIBITORS	60/634,201	12/7/2004		
0832 WO	PTL002210PC	WIPO	UREAS AS FACTOR YA INHIBITORS	PCT/US2005/044388	12/7/2005		
0832 US	PTL002210US	UNITED STATES	UREAS AS FACTOR YA INHIBITORS	11/298,317	12/7/2005	7,678,913	3/16/2010
0833 P1	PTL002300US	UNITED STATES	THIOUREAS AS FACTOR YA INHIBITORS	60/634,150	12/7/2004		
0833 WO	PTL002310PC	WIPO	THIOUREAS AS FACTOR YA INHIBITORS	PCT/US2005/044739	12/7/2005		
0833 US	PTL002310US	UNITED STATES	THIOUREAS AS FACTOR YA INHIBITORS	11/298,296	12/7/2005		
0834 US P1	PTL002400US	UNITED STATES	TETRAHYDROISOQUINOLINES AS FACTOR YA INHIBITORS	60/629,836	11/19/2004		
0834 WO	PTL002410PC	WIPO	TETRAHYDROISOQUINOLINES AS FACTOR YA INHIBITORS	PCT/US2005/042293	11/21/2005		
0834 US	PTL002410US	UNITED STATES	TETRAHYDROISOQUINOLINES AS FACTOR YA INHIBITORS	11/284,805	11/21/2005	7,612,089	11/3/2009
0836 US P1	PTL002700US	UNITED STATES	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	60/733,650	11/3/2005		

PATENT

REEL: 060800 FRAME: 0252

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0836 AR	PTL002710AR	ARGENTINA	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	P060104840	11/3 /2006		
0836 AT	PTL002710AT	AUSTRIA	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	06827506.4	11/3 /2006	1951254	1 /4 /2012
0836 AU	PTL002710AU	AUSTRALIA	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	2006311795	11/3 /2006	2006311795	9 /19/2013
0836 BE	PTL002710BE	BELGIUM	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	06827506.4	11/3 /2006	1951254	1 /4 /2012
0836 BG	PTL002710BG	BULGARIA	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	06827506.4	11/3 /2006	1951254	1 /4 /2012
0836 BR	PTL002710BR	BRAZIL	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	P10618210-0	11/3 /2006		

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0836 CA	PTL002710CA	CANADA	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	2627719	11/3 /2006	2627719	7 /12/2016
0836 CH	PTL002710CH	SWITZERLAND	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	06827506.4	11/3 /2006	1951254	1 /4 /2012
0836 CL	PTL002710CL	CHILE	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	2978-2006	11/3 /2006		
0836 CN	PTL002710CN	CHINA	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	200680041063.5	11/3 /2006	200680041063.5	11/28/2012
0836 CY	PTL002710CY	CYPRUS	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	CY1112826	11/3 /2006	1951254	1 /4 /2012
0836 CZ	PTL002710CZ	CZECH REPUBLIC	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	06827506.4	11/3 /2006	1951254	1 /4 /2012



SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0836 DE	PTL002710DE	GERMANY	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	06827506.4	11/3 /2006	1951254	1 /4 /2012
0836 DK	PTL002710DK	DENMARK	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	06827506.4	11/3 /2006	1951254	1 /4 /2012
0836 EA	PTL002710EA	EURASIAN PATENT	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	200801245	11/3 /2006	017402	12/28/2012
0836 EE	PTL002710EE	ESTONIA	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	06827506.4	11/3 /2006	1951254	1 /4 /2012
0836 EP	PTL002710EP	EUROPEAN PATENT CONVENT	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	06827506.4	11/3 /2006	1951254	1 /4 /2012
0836 ES	PTL002710ES	SPAIN	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	06827506.4	11/3 /2006	1951254	1 /4 /2012

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0836 FI	PTL002710FI	FINLAND	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	06827506.4	11/3 /2006	1951254	1 /4 /2012
0836 FR	PTL002710FR	FRANCE	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	06827506.4	11/3 /2006	1951254	1 /4 /2012
0836 GB	PTL002710GB	UNITED KINGDOM	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	06827506.4	11/3 /2006	1951254	1 /4 /2012
0836 GR	PTL002710GR	GREECE	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	06827506.4	11/3 /2006	1951254	1 /4 /2012
0836 HK	PTL002710HK	HONG KONG	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	09100322.0	11/3 /2006	1121051	6 /8 /2012
0836 IE	PTL002710IE	IRELAND	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	06827506.4	11/3 /2006	1951254	1 /4 /2012

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTFOLIA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0836 IL	PTL002710IL	ISRAEL	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	191193	11/3 /2006	191193	7 /31/2014
0836 IN	PTL002710IN	INDIA	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	1844/KOLNP/2008	11/3 /2006	272457	4 /1 /2016
0836 IT	PTL002710IT	ITALY	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	06827506.4	11/3 /2006	502012902039047	1 /4 /2012
0836 JP	PTL002710JP	JAPAN	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	2008-539089	11/3 /2006	5509406	4 /4 /2014
0836 KR	PTL002710KR	SOUTH KOREA	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	10-2008-7013178	11/3 /2006	10-1423483	7 /21/2014
0836 LU	PTL002710LU	LUXEMBOURG	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	06827506.4	11/3 /2006	1951254	1 /4 /2012

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0836 MT	PTL002710MT	MALTA	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	3873	11/3 /2006	3873	1 /10/2008
0836 MX	PTL002710MX	MEXICO	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	MX/a/2008/005752	11/3 /2006	295448	2 /1 /2012
0836 NL	PTL002710NL	NETHERLANDS	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	06827506.4	11/3 /2006	1951254	1 /4 /2012
0836 NZ	PTL002710NZ	NEW ZEALAND	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	567747	11/3 /2006	567747	3 /5 /2012
0836 WO	PTL002710PC	WIPO	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	PCT/US2006/043093	11/3 /2006		
0836 PE	PTL002710PE	PERU	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	1439-2006	11/13/2006	5913	1 /11/2011

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0836 PT	PTL002710PT	PORTUGAL	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	06827506.4	11/3 /2006	1951254	1 /4 /2012
0836 RU	PTL002710RU	RUSSIA	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	200801245	11/3 /2006	017402	12/28/2012
0836 SE	PTL002710SE	SWEDEN	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	06827506.4	11/3 /2006	1951254	1 /4 /2012
0836 SG	PTL002710SG	SINGAPORE	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	200803140-3	11/3 /2006		
0836 SK	PTL002710SK	SLOVAK REPUBLIC	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	06827506.4	11/3 /2006	1951254	1 /4 /2012
0836 TH	PTL002710TH	THAILAND	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	0601005459	11/3 /2006		

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0836 TR	PTL002710TR	TURKEY	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	06827506.4	11/3 /2006	2012 03793	1 /4 /2012
0836 TW	PTL002710TW	TAIWAN	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	95140753	11/3 /2006	1397529	6 /1 /2013
0836 US	PTL002710US	UNITED STATES	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	11/556.490	11/3 /2006	8,058,284	11/15/2011
0836 VE	PTL002710VE	VENEZUELA	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	2006-02544	11/14/2006		
0836 ZA	PTL002710ZA	SOUTH AFRICA	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	2008/04241	11/3 /2006	2008/04214	9 /30/2009
0836 EP D1	PTL002711EP	EUROPEAN PATENT CONVENT	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	11176014.6	11/3 /2006		

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTFOLIA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0836 IN D1	PTL002711IN	INDIA	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	3825/KOLNP/2009	11/3 /2006		
0836 MX D1	PTL002711MX	MEXICO	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	MX/a/2012/001113	11/3 /2006		
0836 NZ D1	PTL002711NZ	NEW ZEALAND	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	596025	11/3 /2006	596025	12/3 /2013
0836 SG D1	PTL002711SG	SINGAPORE	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	2010081487	11/3 /2006	166833	10/14/2014
0836 US C1	PTL002711US	UNITED STATES	[4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO	13/271,037	10/11/2011		
0837 US P1	PTL002800US	UNITED STATES	K <sup>+</sup> CHANNEL INHIBITORS AND PLATELET PROCOAGULANT ACTIVITY	60/786,163	3/27/2006		
0837 US P2	PTL002801US	UNITED STATES	POTASSIUM CHANNEL MODULATORS AND PLATELET PROCOAGULANT ACTIVITY	60/794,106	4/24/2006		
0837 WO	PTL002810PC	WIPO	POTASSIUM CHANNEL MODULATORS AND PLATELET PROCOAGULANT ACTIVITY	PCT/US2007/064956	3/26/2007		
0837 US	PTL002810US	UNITED STATES	POTASSIUM CHANNEL MODULATORS AND PLATELET PROCOAGULANT ACTIVITY	12/280,531	12/5 /2008		

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0838 US P2	PTL002910US	UNITED STATES	USE OF TP MODULATORS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS IN ASPIRIN SENSITIVE AND OTHER POPULATIONS	60/915,784	5/3/2007		
0838 US P3	PTL002920US	UNITED STATES	USE OF TP MODULATORS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS IN ASPIRIN SENSITIVE AND OTHER POPULATIONS	60/947,289	6/29/2007		
0838 AU	PTL002910AU	AUSTRALIA	USE OF TP MODULATORS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS IN ASPIRIN SENSITIVE AND OTHER POPULATIONS	2008247439	5/12/2008		
0838 CA	PTL002910CA	CANADA	USE OF TP MODULATORS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS IN ASPIRIN SENSITIVE AND OTHER POPULATIONS	2,688,317	5/12/2008		
0838 CN	PTL002910CN	CHINA	USE OF TP MODULATORS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS IN ASPIRIN SENSITIVE AND OTHER POPULATIONS	200880014605.9	5/12/2008		
0838 EP	PTL002910EP	EUROPEAN PATENT CONVENT	USE OF TP MODULATORS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS IN ASPIRIN SENSITIVE AND OTHER POPULATIONS	08747593.5	5/12/2008		
0838 HK	PTL002910HK	HONG KONG	USE OF TP MODULATORS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS IN ASPIRIN SENSITIVE AND OTHER POPULATIONS	10106577.6	5/12/2008		
0838 IL	PTL002910IL	ISRAEL	USE OF TP MODULATORS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS IN ASPIRIN SENSITIVE AND OTHER POPULATIONS	201885	5/12/2008		
0838 JP	PTL002910JP	JAPAN	USE OF TP MODULATORS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS IN ASPIRIN SENSITIVE AND OTHER POPULATIONS	2010-506698	5/12/2008		

PATENT

REEL: 060800 FRAME: 0262



SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTFOLIA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0838 KR	PTL002910KR	SOUTH KOREA	USE OF TP MODULATORS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS IN ASPIRIN SENSITIVE AND OTHER POPULATIONS	10-2009-7025329	5/12/2008		
0838 MX	PTL002910MX	MEXICO	USE OF TP MODULATORS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS IN ASPIRIN SENSITIVE AND OTHER POPULATIONS	MX/a/2009/011745	5/12/2008		
0838 NZ	PTL002910NZ	NEW ZEALAND	USE OF TP MODULATORS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS IN ASPIRIN SENSITIVE AND OTHER POPULATIONS	581198	5/12/2008		
0838 WO	PTL002910PC	WIPO	USE OF TP MODULATORS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS IN ASPIRIN SENSITIVE AND OTHER POPULATIONS	PCT/US2008/062565	5/12/2008		
0838 SG	PTL002910SG	SINGAPORE	USE OF TP MODULATORS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS IN ASPIRIN SENSITIVE AND OTHER POPULATIONS	200907029-3	5/12/2008		
0838 US	PTL002910US	UNITED STATES	USE OF TP MODULATORS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS IN ASPIRIN SENSITIVE AND OTHER POPULATIONS	12/114,642	5/12/2008		
0838 ZA	PTL002910ZA	SOUTH AFRICA	USE OF TP MODULATORS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS IN ASPIRIN SENSITIVE AND OTHER POPULATIONS	2009/08514	5/12/2008		
0840 US P1	PTL003100US	UNITED STATES	PLATELET ADP RECEPTOR INHIBITORS NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	60/846,328	9/120/2006		
0840 AE	PTL003110AE	UNITED ARAB EMR	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	260/2009	9/120/2007		
0840 AU	PTL003110AU	AUSTRALIA	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	2007299723	9/120/2007		

PATENT

REEL: 060800 FRAME: 0263

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTFOLIA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0840 BR	PTL003110BR	BRAZIL	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	PI0718444-1	9/20/2007		
0840 CA	PTL003110CA	CANADA	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	2664411	9/20/2007		
0840 CH	PTL003110CH	SWITZERLAND	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	07842909.9	9/20/2007	2094272	3/26/2014
0840 CN	PTL003110CN	CHINA	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	200780042200.1	9/20/2007		
0840 CO	PTL003110CO	COLOMBIA	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	09-029.291	9/20/2007		
0840 DE	PTL003110DE	GERMANY	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	07842909.9	9/20/2007	2094272	3/26/2014
0840 DZ	PTL003110DZ	ALGERIA	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	090171	9/20/2007		
0840 EC	PTL003110EC	EQUADOR	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	SP-09-9198	9/20/2007		
0840 EG	PTL003110EG	EGYPT	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	PCT/367/2009	9/20/2007		
0840 EP	PTL003110EP	EUROPEAN PATENT CONVENT	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	07842909.9	9/20/2007	2094272	3/26/2014
0840 FR	PTL003110FR	FRANCE	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	07842909.9	9/20/2007	2094272	3/26/2014

PATENT

REEL: 060800 FRAME: 0264

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0840 GB	PTL003110GB	UNITED KINGDOM	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	07842909.9	9/20/2007	2094272	3/26/2014
0840 GT	PTL003110GT	GUATEMALA	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	A-2009-00066	9/20/2007		
0840 HK	PTL003110HK	HONG KONG	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	09110735.0	9/20/2007	1131058	7/18/2014
0840 ID	PTL003110ID	INDONESIA	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	W00200900728	9/20/2007		
0840 IE	PTL003110IE	IRELAND	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	07842909.9	9/20/2007	2094272	3/26/2014
0840 IL	PTL003110IL	ISRAEL	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	197726	9/20/2007		
0840 IN	PTL003110IN	INDIA	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	2570/DELNP/2009	9/20/2007		
0840 JP	PTL003110JP	JAPAN	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	2009-529403	9/20/2007	5266232	5/10/2013
0840 KR	PTL003110KR	SOUTH KOREA	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	10-2009-7007782	9/20/2007		
0840 LU	PTL003110LU	LUXEMBOURG	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	07842909.9	9/20/2007	2094272	3/26/2014
0840 MA	PTL003110MA	MOROCCO	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	PV/31756	9/20/2007	30775	10/1/2009

PATENT

REEL: 060800 FRAME: 0265

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0840 MC	PTL003110MC	MONACO	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	07842909.9	9/20/2007	2094272	3/26/2014
0840 MX	PTL003110MX	MEXICO	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	MX/a/2009/003017	9/20/2007	297848	4/3/2012
0840 MY	PTL003110MY	MALAYSIA	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	P/20091123	9/20/2007		
0840 NO	PTL003110NO	NORWAY	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	20091331	9/20/2007		
0840 NZ	PTL003110NZ	NEW ZEALAND	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	576162	9/20/2007	576162	7/9/2012
0840 WO	PTL003110PC	WIPO	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	PCT/US2007/079076	9/20/2007		
0840 PH	PTL003110PH	PHILIPPINES	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	1-2009-500513	9/20/2007		
0840 RU	PTL003110RU	RUSSIA	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	2009114827	9/20/2007		
0840 SG	PTL003110SG	SINGAPORE	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	200901894-6	9/20/2007	151396	10/31/2011
0840 TN	PTL003110TN	TUNISIA	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	TN2009/0091	9/20/2007		
0840 TW	PTL003110TW	TAIWAN	PLATELET ADP RECEPTOR INHIBITORS	96135115	9/20/2007		
0840 US	PTL003110US	UNITED STATES	SUBSTITUTED DIHYDROQUINAZOLINES AS PLATELET ADP RECEPTOR INHIBITORS	11/856,616	9/17/2007	7,834,023	11/16/2010

PATENT

REEL: 060800 FRAME: 0266

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0840 ZA	PTL003110ZA	SOUTH AFRICA	NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS	2009/02082	9/20/2007	2009/02082	3/31/2010
0840 US D1	PTL003111US	UNITED STATES	SUBSTITUTED DIHYDROQUINAZOLINES AS PLATELET ADP RECEPTOR INHIBITORS	12/912,367	10/26/2010		
0841 US P1	PTL003200US	UNITED STATES	TARGETED DELIVERY AND EXPRESSION OF PROCOAGULANT HEMOSTATIC ACTIVITY	60/908,575	3/28/2007		
0841 WO	PTL003210PC	WIPO	TARGETED DELIVERY AND EXPRESSION OF PROCOAGULANT HEMOSTATIC ACTIVITY	PCT/US2008/058469	3/27/2008		
0841 US	PTL003210US	UNITED STATES	TARGETED DELIVERY AND EXPRESSION OF PROCOAGULANT HEMOSTATIC ACTIVITY	12/057,100	3/27/2008		
0842 US P1	PTL003400US	UNITED STATES	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHOD OF USE	60/976,343	9/28/2007		
0842 US P2	PTL003401US	UNITED STATES	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	61/090,574	8/20/2008		
0842 AT	PTL003410AT	AUSTRIA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016
0842 AU	PTL003410AU	AUSTRALIA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	2008304192	9/26/2008	2008304192	8/28/2014
0842 BE	PTL003410BE	BELGIUM	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016
0842 BG	PTL003410BG	BULGARIA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016
0842 BR	PTL003410BR	BRAZIL	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	PI0816837-7	9/26/2008		
0842 CA	PTL003410CA	CANADA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	2697583	9/26/2008	2697583	4/12/2016
0842 CH	PTL003410CH	SWITZERLAND	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0842 CN	PTL003410CN	CHINA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	200880107973.8	9/26/2008	ZL200880107973.8	8/21/2013
0842 CY	PTL003410CY	CYPRUS	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016
0842 CZ	PTL003410CZ	CZECH REPUBLIC	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016
0842 DE	PTL003410DE	GERMANY	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016
0842 DK	PTL003410DK	DENMARK	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016
0842 EE	PTL003410EE	ESTONIA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016
0842 EP	PTL003410EP	EUROPEAN PATENT CONVENT	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016
0842 ES	PTL003410ES	SPAIN	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016
0842 FI	PTL003410FI	FINLAND	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016
0842 FR	PTL003410FR	FRANCE	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016
0842 GB	PTL003410GB	UNITED KINGDOM	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016
0842 GR	PTL003410GR	GREECE	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016
0842 HK	PTL003410HK	HONG KONG	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	10109954.3	9/26/2008	1143398	10/6/2017
0842 HR	PTL003410HR	CROATIA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016
0842 HU	PTL003410HU	HUNGARY	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016

PATENT

REEL: 060800 FRAME: 0268

SCHEDULE A  
Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0842 IE	PTL003410IE	IRELAND	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016
0842 IL	PTL003410IL	ISRAEL	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	203993	9/26/2008	203993	3/1/2018
0842 IN	PTL003410IN	INDIA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	962/KOLNP/2010	9/26/2008	311668	4/25/2019
0842 IS	PTL003410IS	ICELAND	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016
0842 IT	PTL003410IT	ITALY	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016
0842 JP	PTL003410JP	JAPAN	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	2010-527220	9/26/2008	5637561	10/31/2014
0842 KR	PTL003410KR	SOUTH KOREA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	10-2010-7008718	9/26/2008	10-1698214	1/13/2017
0842 LT	PTL003410LT	LITHUANIA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016
0842 LU	PTL003410LU	LUXEMBOURG	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016
0842 LV	PTL003410LV	LATVIA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016
0842 MC	PTL003410MC	MONACO	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016
0842 MT	PTL003410MT	MALTA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016
0842 MX	PTL003410MX	MEXICO	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	MX/a/2010/003095	9/26/2008	325841	12/1/2014
0842 NL	PTL003410NL	NETHERLANDS	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016
0842 NO	PTL003410NO	NORWAY	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016

SCHEDULE A  
Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0842 NZ	PTL003410NZ	NEW ZEALAND	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	583944	9/26/2008	583944	10/8/2012
0842 WO	PTL003410PC	WIPO	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHOD OF USING THE SAME	PCT/US2008/078014	9/26/2008		
0842 PL	PTL003410PL	POLAND	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016
0842 PT	PTL003410PT	PORTUGAL	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016
0842 RO	PTL003410RO	ROMANIA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016
0842 SE	PTL003410SE	SWEDEN	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016
0842 SG	PTL003410SG	SINGAPORE	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	201001094-0	9/26/2008		
0842 SI	PTL003410SI	SLOVENIA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016
0842 SK	PTL003410SK	SLOVAK REPUBLIC	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016
0842 TR	PTL003410TR	TURKEY	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	08834136.7	9/26/2008	2193196	7/13/2016
0842 US	PTL003410US	UNITED STATES	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	12/239.651	9/26/2008	8,153,590	4/10/2012
0842 ZA	PTL003410ZA	SOUTH AFRICA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	2010/02039	9/26/2008	2010/02039	11/25/2015
0842 AU D1	PTL003411AU	AUSTRALIA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	2013205326	9/26/2008		
0842 CN D1	PTL003411CN	CHINA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	201110447205.0	9/26/2008		
0842 EP D1	PTL003411EP	EUROPEAN PATENT CONVENT	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	14197779.3	9/26/2008	2915564	11/4/2020



SCHEDULE A  
Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTFOLIA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0842 HK D1	PTL003411HK	HONG KONG	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	13100121.7	9/26/2008		
0842 IL D1	PTL003411IL	ISRAEL	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	255397	9/26/2008	255397	7/1/2019
0842 JP D1	PTL003411JP	JAPAN	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	2014-166333	9/26/2008	6047127	11/25/2016
0842 KR D1	PTL003411KR	SOUTH KOREA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	10-2016-7003860	9/26/2008	10-2069498	1/17/2020
0842 SG D1	PTL003411SG	SINGAPORE	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	201207271-6	9/26/2008	185263	2/27/2015
0842 US C1	PTL003411US	UNITED STATES	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	13/414,499	3/7/2012	8,455,441	6/4/2013
0842 ZA D1	PTL003411ZA	SOUTH AFRICA	ANTIDOTES FOR FACTOR XA INHIBITORS	2014/06514	9/26/2008	2014/06514	10/26/2016
0842 AT D2	PTL003412AT	AUSTRIA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020
0842 AU D2	PTL003412AU	AUSTRALIA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	2014210620	9/26/2008	2014210620	8/25/2016
0842 BE D2	PTL003412BE	BELGIUM	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020
0842 BG D2	PTL003412BG	BULGARIA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020
0842 CH D2	PTL003412CH	SWITZERLAND	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020
0842 CN D2	PTL003412CN	CHINA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	201110447251.0	9/26/2008	ZL201110447251.0	3/25/2015
0842 CY D2	PTL003412CY	CYPRUS	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020
0842 CZ D2	PTL003412CZ	CZECH REPUBLIC	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020
0842 DE D2	PTL003412DE	GERMANY	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020

SCHEDULE A  
Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0842 DK D2	PTL003412DK	DENMARK	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020
0842 EE D2	PTL003412EE	ESTONIA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020
0842 EP D2	PTL003412EP	EUROPEAN PATENT CONVENT	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020
0842 ES D2	PTL003412ES	SPAIN	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020
0842 FI D2	PTL003412FI	FINLAND	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020
0842 FR D2	PTL003412FR	FRANCE	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020
0842 GB D2	PTL003412GB	UNITED KINGDOM	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020
0842 GR D2	PTL003412GR	GREECE	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020
0842 HK EP D1	PTL003412HK	HONG KONG	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	1511214.0	9/26/2008	3078743	6/24/2020
0842 HR D2	PTL003412HR	CROATIA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020
0842 HU D2	PTL003412HU	HUNGARY	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020
0842 IE D2	PTL003412IE	IRELAND	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020
0842 IL D2	PTL003412IL	ISRAEL	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	264886	9/26/2008	264886	7/1/2020
0842 IS D2	PTL003412IS	ICELAND	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020
0842 IT D2	PTL003412IT	ITALY	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0842 JP D2	PTL003412JP	JAPAN	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	2016-225290	9/26/2008	6300885	3/9/2018
0842 KR D2	PTL003412KR	SOUTH KOREA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	10-2017-7023761	9/26/2008		
0842 LT D2	PTL003412LT	LITHUANIA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020
0842 LU D2	PTL003412LU	LUXEMBOURG	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020
0842 LV D2	PTL003412LV	LATVIA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020
0842 MC D2	PTL003412MC	MONACO	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020
0842 MT D2	PTL003412MT	MALTA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020
0842 NL D2	PTL003412NL	NETHERLANDS	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020
0842 NO D2	PTL003412NO	NORWAY	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020
0842 PL D2	PTL003412PL	POLAND	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020
0842 PT D2	PTL003412PT	PORTUGAL	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020
0842 RO D2	PTL003412RO	ROMANIA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020
0842 SE D2	PTL003412SE	SWEDEN	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020
0842 SI D2	PTL003412SI	SLOVENIA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020
0842 SK D2	PTL003412SK	SLOVAK REPUBLIC	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020

SCHEDULE A  
Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0842 TR D2	PTL003412TR	TURKEY	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16167534.3	9/26/2008	3078743	6/24/2020
0842 US C2	PTL003412US	UNITED STATES	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	13/889,014	5/17/2013	9,062,298	6/23/2015
0842 AU D3	PTL003413AU	AUSTRALIA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	2017200212	9/26/2008		
0842 CN D3	PTL003413CN	CHINA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	201310301566.3	9/26/2008	ZL201310301566.3	4/22/2015
0842 EP D3	PTL003413EP	EUROPEAN PATENT CONVENT	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	20198287.3	9/26/2008		
0842 HK EP D2	PTL003413HK	HONG KONG	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	17103363.4	9/26/2008		
0842 IL D3	PTL003413IL	ISRAEL	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	272926	9/26/2008		
0842 JP D2	PTL003413JP	JAPAN	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	2018-33229	9/26/2008		
0842 KR D2	PTL003413KR	SOUTH KOREA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	10-2020-7001549	9/26/2008		
0842 US C3	PTL003413US	UNITED STATES	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	13/915,525	6/11/2013	8,889,129	11/18/2014
0842 AU D4	PTL003414AU	AUSTRALIA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	2019204123	9/26/2008		
0842 JP D4	PTL003414JP	JAPAN	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	2020-42919	9/26/2008		
0842 US C4	PTL003414US	UNITED STATES	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	14/337,074	7/21/2014	9,388,401	7/12/2016
0842 US C5	PTL003415US	UNITED STATES	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	15/176,461	6/8/2016	10,675,335	6/9/2020
0842 US C6	PTL003416US	UNITED STATES	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16/869,117	5/17/2020		

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0842 AT SPC	PTL003410ATSPC	AUSTRIA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	SZ 51/2019	10/24/2019		
0842 BE SPC	PTL003410BESPC	BELGIUM	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	2019C/546	10/24/2019		
0842 DE SPC	PTL003410DESPC	GERMANY	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	122019000093.3	10/25/2019		
0842 DK SPC	PTL003410DKSPC	DENMARK	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	CA 2019 00053	10/25/2019		
0842 ES SPC	PTL003410ESSPC	SPAIN	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	C201930064	10/24/2019		
0842 FI SPC	PTL003410FISPC	FINLAND	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	C20190049	10/25/2019		
0842 FR SPC	PTL003410FRSPC	FRANCE	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	19C1064	10/24/2019		
0842 GB SPC	PTL003410GBSPC	UNITED KINGDOM	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	SPC/GB19/065	10/24/2019		
0842 GR SPC	PTL003410GRSPC	GREECE	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	20190800048	10/23/2019		
0842 IE SPC	PTL003410IESPC	IRELAND	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	2019/053	10/25/2019		
0842 IT SPC	PTL003410ITSPC	ITALY	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	132019000000141	10/25/2019		
0842 NL SPC	PTL003410NLSPC	NETHERLANDS	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	301014	10/24/2019		
0842 NO SPC	PTL003410NOSPC	NORWAY	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	2019040	11/8/2019		
0842 PL SPC	PTL003410PLSPC	POLAND	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	DPO.0598	10/23/2019		
0842 PT SPC	PTL003410PTSPC	PORTUGAL	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	1000	10/24/2019		

PATENT

REEL: 060800 FRAME: 0275

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO.	FILE DATE	PATENT NO.	ISSUE DATE
0842 SE SPC	PTL003410SESPC	SWEDEN	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	1990052-1	10/28/2019	1990052-1	11/28/2019
0842 AT D2 SPC	PTL003412ATSPC	AUSTRIA	ANTIDOTES FOR FACTOR XA INHIBITORS	SZ39/2020	9/11/2020		
0842 BE D2 SPC	PTL003412BESPC	BELGIUM	ANTIDOTES FOR FACTOR XA INHIBITORS	2020C/537	9/29/2020		
0842 BG D2 SPC	PTL003412BGSPC	BULGARIA	ANTIDOTES FOR FACTOR XA INHIBITORS	SPC of EP3078743			
0842 CY D2 SPC	PTL003412CYSPPC	CYPRUS	ANTIDOTES FOR FACTOR XA INHIBITORS	SPC of EP3078743			
0842 CZ D2 SPC	PTL003412CZSPC	CZECH REPUBLIC	ANTIDOTES FOR FACTOR XA INHIBITORS	SPC of EP3078743			
0842 DE D2 SPC	PTL003412DESPC	GERMANY	ANTIDOTES FOR FACTOR XA INHIBITORS	SPC of EP3078743			
0842 DK D2 SPC	PTL003412DKSPC	DENMARK	ANTIDOTES FOR FACTOR XA INHIBITORS	CA 2020 00044	9/15/2020		
0842 EE D2 SPC	PTL003412EESPC	ESTONIA	ANTIDOTES FOR FACTOR XA INHIBITORS	SPC of EP3078743			
0842 ES D2 SPC	PTL003412ESSPC	SPAIN	ANTIDOTES FOR FACTOR XA INHIBITORS	202030048	9/30/2020		
0842 FI D2 SPC	PTL003412FISPC	FINLAND	ANTIDOTES FOR FACTOR XA INHIBITORS	C20200041	10/19/2020		
0842 FR D2 SPC	PTL003412FRSPC	FRANCE	ANTIDOTES FOR FACTOR XA INHIBITORS	20C1045	9/23/2020		
0842 GB D2 SPC	PTL003412GBSPC	UNITED KINGDOM	ANTIDOTES FOR FACTOR XA INHIBITORS	SPC of EP3078743			
0842 GR D2 SPC	PTL003412GRSPC	GREECE	ANTIDOTES FOR FACTOR XA INHIBITORS	20200800036	9/9/2020		
0842 HR D2 SPC	PTL003412HRSPC	CROATIA	ANTIDOTES FOR FACTOR XA INHIBITORS	SPC of EP3078743			
0842 HU D2 SPC	PTL003412HUSPC	HUNGARY	ANTIDOTES FOR FACTOR XA INHIBITORS	SPC of EP3078743			
0842 IE D2 SPC	PTL003412IESPC	IRELAND	ANTIDOTES FOR FACTOR XA INHIBITORS	2020/046	10/15/2020		
0842 IS D2 SPC	PTL003412ISSPC	ICELAND	ANTIDOTES FOR FACTOR XA INHIBITORS	SPC of EP3078743			
0842 IT D2 SPC	PTL003412ITSPC	ITALY	ANTIDOTES FOR FACTOR XA INHIBITORS	132020000000130	10/16/2020		
0842 LT D2 SPC	PTL003412LTSPPC	LITHUANIA	ANTIDOTES FOR FACTOR XA INHIBITORS	SPC of EP3078743			
0842 LU D2 SPC	PTL003412LUSPC	LUXEMBOURG	ANTIDOTES FOR FACTOR XA INHIBITORS	SPC of EP3078743			
0842 LV D2 SPC	PTL003412LVSPC	LATVIA	ANTIDOTES FOR FACTOR XA INHIBITORS	SPC of EP3078743			

PATENT

REEL: 060800 FRAME: 0276

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0842 MT D2 SPC	PTL003412MTSPC	MALTA	ANTIDOTES FOR FACTOR XA INHIBITORS	SPC of EP3078743			
0842 NL D2 SPC	PTL003412NLSPC	NETHERLANDS	ANTIDOTES FOR FACTOR XA INHIBITORS	301063	9/9/2020		
0842 NO D2 SPC	PTL003412NOSPC	NORWAY	ANTIDOTES FOR FACTOR XA INHIBITORS	2020033	9/23/2020		
0842 PL D2 SPC	PTL003412PLSPC	POLAND	ANTIDOTES FOR FACTOR XA INHIBITORS	DPO.0650	11/6/2020		
0842 PT D2 SPC	PTL003412PTSPC	PORTUGAL	ANTIDOTES FOR FACTOR XA INHIBITORS	1046	9/14/2020		
0842 RO D2 SPC	PTL003412ROSPC	ROMANIA	ANTIDOTES FOR FACTOR XA INHIBITORS	SPC of EP3078743			
0842 SI D2 SPC	PTL003412SISPC	SLOVENIA	ANTIDOTES FOR FACTOR XA INHIBITORS	SPC of EP3078743			
0842 SK D2 SPC	PTL003412SKSPC	SLOVAK REPUBLIC	ANTIDOTES FOR FACTOR XA INHIBITORS	SPC of EP3078743			
0846 MT	PTL003800MT	MALTA	SUBSTITUTED- (QUINAZOLINYL)PHENYL THIOPHENYL-SULFONYLUREAS, METHODS FOR MAKING AND INTERMEDIATES THEREOF	3874	11/3 /2006	3874	1 /10/2008
0846 WO	PTL003800PC	WIPO	SUBSTITUTED- (QUINAZOLINYL)PHENYL THIOPHENYL-SULFONYLUREAS, METHODS FOR MAKING AND INTERMEDIATES THEREOF	PCT/US2006/042998	11/3 /2006		
0846 PE	PTL003800PE	PERU	SUBSTITUTED- (QUINAZOLINYL)PHENYL THIOPHENYL-SULFONYLUREAS, METHODS FOR MAKING AND INTERMEDIATES THEREOF	1438-2006	11/13/2006		
0846 US P1	PTL003800PRO	UNITED STATES	SUBSTITUTED- (QUINAZOLINYL)PHENYL THIOPHENYL-SULFONYLUREAS, METHODS FOR MAKING AND INTERMEDIATES THEREOF	60/733.650	11/3 /2005		
0846 TW	PTL003800TW	TAIWAN	SUBSTITUTED- (QUINAZOLINYL)PHENYL THIOPHENYL-SULFONYLUREAS, METHODS FOR MAKING AND INTERMEDIATES THEREOF	95140749	11/3 /2006		
0846 US	PTL003800US	UNITED STATES	SUBSTITUTED- (QUINAZOLINYL)PHENYL THIOPHENYL-SULFONYLUREAS, METHODS FOR MAKING AND INTERMEDIATES THEREOF	11/556.518	11/3 /2006		

PATENT

REEL: 060800 FRAME: 0277

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0846 VE	PTL003800VE	VENEZUELA	SUBSTITUTED- (QUINAZOLINYL)PHENYL THIOPHENYL-SULFONYLUREAS, METHODS FOR MAKING AND INTERMEDIATES THEREOF	2545-2006	11/14/2006		
0848 US P1	PTL004000US	UNITED STATES	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	60/915,911	5/3/2007		
0848 US P2	PTL004001US	UNITED STATES	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	60/978,700	10/9/2007		
0848 AE	PTL004010AE	UNITED ARAB EMR	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	P9688/09	5/12/2008		
0848 AU	PTL004010AU	AUSTRALIA	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	2008247435	5/12/2008		
0848 BR	PTL004010BR	BRAZIL	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	P10811000-0	5/12/2008		
0848 CA	PTL004010CA	CANADA	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	2684722	5/12/2008		
0848 CH	PTL004010CH	SWITZERLAND	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	08747590.1	5/12/2008	2146705	3/5/2014
0848 CN	PTL004010CN	CHINA	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	200880021658.3	5/12/2008	ZL200880021658.3	5/7/2014
0848 CO	PTL004010CO	COLOMBIA	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	09-132.196	5/12/2008		
0848 DE	PTL004010DE	GERMANY	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	08747590.1	5/12/2008	2146705	3/5/2014



SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0848 DZ	PTL004010DZ	ALGERIA	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	090704	5/12/2008	6845	7/25/2011
0848 EA	PTL004010EA	EURASIAN PATENT	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	200901442	5/12/2008	020045	8/29/2014
0848 EC	PTL004010EC	EQUADOR	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	SP-09-9775	5/12/2008		
0848 EG	PTL004010EG	EGYPT	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	PCT1585/2009	5/12/2008		
0848 EP	PTL004010EP	EUROPEAN PATENT CONVENT	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	08747590.1	5/12/2008	2146705	3/5/2014
0848 ES	PTL004010ES	SPAIN	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	08747590.1	5/12/2008	2146705	3/5/2014
0848 FR	PTL004010FR	FRANCE	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	08747590.1	5/12/2008	2146705	3/5/2014
0848 GB	PTL004010GB	UNITED KINGDOM	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	08747590.1	5/12/2008	2146705	3/5/2014
0848 GT	PTL004010GT	GUATEMALA	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	A2009-00283	5/12/2008		
0848 HK	PTL004010HK	HONG KONG	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	10105391.2	5/12/2008	1138765	9/5/2014
0848 ID	PTL004010ID	INDONESIA	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	W00200903017	5/12/2008		

PATENT

REEL: 060800 FRAME: 0279

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTFOLIA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0848 IE	PTL004010IE	IRELAND	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	08747590.1	5/12/2008	2146705	3/5/2014
0848 IL	PTL004010IL	ISRAEL	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	201826	5/12/2008	201826	12/1/2014
0848 IN	PTL004010IN	INDIA	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	7079/DELNP/2009	5/12/2008		
0848 JP	PTL004010JP	JAPAN	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	2010-506696	5/12/2008	5439363	12/20/2013
0848 KR	PTL004010KR	SOUTH KOREA	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	10-2009-7024870	5/12/2008	10-1509829	4/1/2015
0848 MA	PTL004010MA	MOROCCO	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	PV/32375	5/12/2008	31396	5/3/2010
0848 MX	PTL004010MX	MEXICO	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	MX/a/2009/011755	5/12/2008	321993	7/15/2014
0848 MY	PTL004010MY	MALAYSIA	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	P/20094513	5/12/2008		
0848 NZ	PTL004010NZ	NEW ZEALAND	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	581324	5/12/2008	581324	9/3/2012
0848 WO	PTL004010PC	WIPO	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	PCT/US2008/062361	5/12/2008		
0848 PH	PTL004010PH	PHILIPPINES	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	1-2009-501982	5/12/2008		

PATENT

REEL: 060800 FRAME: 0280

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0848 PT	PTL004010PT	PORTUGAL	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	08747590.1	5/12/2008	2146705	3/5/2014
0848 RU	PTL004010RU	RUSSIA	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	200901442	5/12/2008	020045	8/29/2014
0848 SG	PTL004010SG	SINGAPORE	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	200906856-0	5/12/2008		
0848 TN	PTL004010TN	TUNISIA	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	TN2009/0444	5/12/2008		
0848 US	PTL004010US	UNITED STATES	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	12/114,706	5/12/2008		
0848 ZA	PTL004010ZA	SOUTH AFRICA	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	2009/07165	5/12/2008	2009/07165	8/31/2011
0848 EP D1	PTL004011EP	EUROPEAN PATENT CONVENT	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	13151486.1	5/12/2008		
0848 HK D1	PTL004011HK	HONG KONG	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	13112057.0	5/12/2008		
0848 NZ D1	PTL004011NZ	NEW ZEALAND	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	599556	5/12/2008		
0848 SG D1	PTL004011SG	SINGAPORE	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	201203232-2	5/12/2008	181304	11/3/2015
0848 US C1	PTL004011US	UNITED STATES	COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR	12/908,837	10/20/2010	8,946,219	2/3/2015

PATENT

REEL: 060800 FRAME: 0281

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTFOLIA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0851 US P1	PTL004400US	UNITED STATES	THROMBOXANE RECEPTOR (TP) ANTAGONISTS FOR TREATING OR PREVENTING THROMBOSIS PRE- AND POST-SURGERY IN PATIENTS RECEIVING ANTI-PLATELET NSAID THERAPY	61/420,691	12/7 /2010		
0852 US P1	PTL004500US	UNITED STATES	UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH THROMBOXANE RECEPTOR ANTAGONISTS	60/915,785	5/3/2007		
0852 US P2	PTL004501US	UNITED STATES	UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH THROMBOXANE RECEPTOR ANTAGONISTS	60/947,316	6 /29/2007		
0852 AU	PTL004510AU	AUSTRALIA	UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH THROMBOXANE RECEPTOR ANTAGONISTS	2008247441	5 /2 /2008		
0852 CA	PTL004510CA	CANADA	UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH THROMBOXANE RECEPTOR ANTAGONISTS	2688319	5 /2 /2008		
0852 CN	PTL004510CN	CHINA	UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH THROMBOXANE RECEPTOR ANTAGONISTS	200880019332.7	5 /2 /2008		
0852 EP	PTL004510EP	EUROPEAN PATENT CONVENT	UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH THROMBOXANE RECEPTOR ANTAGONISTS	08747595.0	5 /2 /2008		
0852 HK	PTL004510HK	HONG KONG	UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH THROMBOXANE RECEPTOR ANTAGONISTS	10106578.5	5 /2 /2008		
0852 IL	PTL004510IL	ISRAEL	UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH THROMBOXANE RECEPTOR ANTAGONISTS	201886	5 /2 /2008		

PATENT

REEL: 060800 FRAME: 0282

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0852 IN	PTL004510IN	INDIA	UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH THROMBOXANE RECEPTOR ANTAGONISTS	7859/DELNP/2009	5/12/2008		
0852 JP	PTL004510JP	JAPAN	UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH THROMBOXANE RECEPTOR ANTAGONISTS	2010-506700	5/12/2008		
0852 KR	PTL004510KR	SOUTH KOREA	UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH THROMBOXANE RECEPTOR ANTAGONISTS	10-2009-7025330	5/12/2008		
0852 MX	PTL004510MX	MEXICO	UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH THROMBOXANE RECEPTOR ANTAGONISTS	MX/a/2009/011744	5/12/2008		
0852 NZ	PTL004510NZ	NEW ZEALAND	UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH THROMBOXANE RECEPTOR ANTAGONISTS	581197	5/12/2008		
0852 WO	PTL004510PC	WIPO	UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH THROMBOXANE RECEPTOR ANTAGONISTS	PCT/US2008/062567	5/12/2008		
0852 SG	PTL004510SG	SINGAPORE	UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH THROMBOXANE RECEPTOR ANTAGONISTS	200907020-2	5/12/2008		
0852 US	PTL004510US	UNITED STATES	UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH THROMBOXANE RECEPTOR ANTAGONISTS	12/114,646	5/12/2008		
0852 ZA	PTL004510ZA	SOUTH AFRICA	UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH THROMBOXANE RECEPTOR ANTAGONISTS	2009/08463	5/12/2008		

PATENT

REEL: 060800 FRAME: 0283

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0853 US P1	PTL004900US	UNITED STATES	INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR	60/915,649	5/12/2007		
0853 US P2	PTL004901US	UNITED STATES	INTRAVENOUS DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR	60/947,921	7/3/2007		
0853 AE	PTL004910AE	UNITED ARAB EMR	INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR	P989/09	5/12/2008		
0853 AU	PTL004910AU	AUSTRALIA	INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR	2008247483	5/12/2008		
0853 BR	PTL004910BR	BRAZIL	INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR	P10811476-5	5/12/2008		
0853 CA	PTL004910CA	CANADA	INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR	2686203	5/12/2008		
0853 CN	PTL004910CN	CHINA	INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR	200880023071.6	5/12/2008		
0853 CO	PTL004910CO	COLOMBIA	INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR	09-137.697	5/12/2008		
0853 DZ	PTL004910DZ	ALGERIA	INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR	090706	5/12/2008		
0853 EA	PTL004910EA	EURASIAN PATENT	INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR	200901473	5/12/2008		
0853 EC	PTL004910EC	ECUADOR	INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR	SP-09-9778	5/12/2008		
0853 EG	PTL004910EG	EGYPT	INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR	PCT1611/2009	5/12/2008		

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0853 EP	PTL004910EP	EUROPEAN PATENT CONVENT	INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR	08747561.2	5/12/2008		
0853 GT	PTL004910GT	GUATEMALA	INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR	A2009-00284	5/12/2008		
0853 HK	PTL004910HK	HONG KONG	INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR	09111676.9	5/12/2008		
0853 ID	PTL004910ID	INDONESIA	INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR	W00200903042	5/12/2008		
0853 IL	PTL004910IL	ISRAEL	INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR	201834	5/12/2008		
0853 IN	PTL004910IN	INDIA	INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR	7682/DELNP/2009	5/12/2008		
0853 JP	PTL004910JP	JAPAN	INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR	2010-506688	5/12/2008		
0853 KR	PTL004910KR	SOUTH KOREA	INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR	10-2009-7025059	5/12/2008		
0853 MA	PTL004910MA	MOROCCO	INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR	PV/32377	5/12/2008	31663	9/1/2010
0853 MX	PTL004910MX	MEXICO	INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR	MX/a/2009/011843	5/12/2008		
0853 MY	PTL004910MY	MALAYSIA	INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR	P120094560	5/12/2008		

PATENT

REEL: 060800 FRAME: 0285

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0853 NZ	PTL004910NZ	NEW ZEALAND	INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR	581322	5/12/2008		
0853 WO	PTL004910PC	WIPO	INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR	PCT/US2008/062518	5/12/2008		
0853 PH	PTL004910PH	PHILIPPINES	INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR	1-2009-502068	5/12/2008		
0853 SG	PTL004910SG	SINGAPORE	INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR	200907136-6	5/12/2008		
0853 TN	PTL004910TN	TUNISIA	INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR	TN2009/0451	5/12/2008		
0853 US	PTL004910US	UNITED STATES	INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR	12/114,630	5/12/2008		
0853 ZA	PTL004910ZA	SOUTH AFRICA	INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR	2009/07568	5/12/2008	2009/07568	8/25/2010
0853 US C1	PTL004911US	UNITED STATES	[4-6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL]-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS, AND METHODS RELATED	13/235,305	9/16/2011		
0854 US P1	PTL005000US	UNITED STATES	[4-6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL]-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS, AND METHODS RELATED	60/927,328	5/12/2007		
0854 AE	PTL005010AE	UNITED ARAB EMR	[4-6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL]-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS, AND METHODS RELATED	P990/09	5/12/2008		



SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0854 AU	PTL005010AU	AUSTRALIA	[4-6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS, AND METHODS RELATED	2008247457	5/12/2008		
0854 BR	PTL005010BR	BRAZIL	[4-6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS, AND METHODS RELATED	PI0810800-5	5/12/2008		
0854 CA	PTL005010CA	CANADA	[4-6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS, AND METHODS RELATED	2686221	5/12/2008		
0854 CN	PTL005010CN	CHINA	[4-6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS, AND METHODS RELATED	200880022604.9	5/12/2008		
0854 CO	PTL005010CO	COLOMBIA	[4-6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS, AND METHODS RELATED	09-132.279	5/12/2008		
0854 DZ	PTL005010DZ	ALGERIA	[4-6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS, AND METHODS RELATED	090705	5/12/2008	6885	7/12/2011
0854 EA	PTL005010EA	EURASIAN PATENT	[4-6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS, AND METHODS RELATED	200901474	5/12/2008		
0854 EC	PTL005010EC	EQUADOR	[4-6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS, AND METHODS RELATED	SP-09-9779	5/12/2008		

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0854 EG	PTL005010EG	EGYPT	[4-6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS, AND METHODS RELATED	PCT1610/2009	5/12/2008		
0854 EP	PTL005010EP	EUROPEAN PATENT CONVENT	[4-6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS, AND METHODS RELATED	08747609.9	5/12/2008		
0854 GT	PTL005010GT	GUATEMALA	[4-6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS, AND METHODS RELATED	A2009-00282	5/12/2008		
0854 HK	PTL005010HK	HONG KONG	[4-6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS, AND METHODS RELATED	9112047.9	5/12/2008		
0854 ID	PTL005010ID	INDONESIA	[4-6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS, AND METHODS RELATED	W00200903041	5/12/2008		
0854 IL	PTL005010IL	ISRAEL	[4-6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS, AND METHODS RELATED	201829	5/12/2008		
0854 IN	PTL005010IN	INDIA	[4-6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS, AND METHODS RELATED	7683/DELNP/2009	5/12/2008		
0854 JP	PTL005010JP	JAPAN	[4-6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS, AND METHODS RELATED	2010-506707	5/12/2008		

PATENT

REEL: 060800 FRAME: 0288

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0854 KR	PTL005010KR	SOUTH KOREA	[4-6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS, AND METHODS RELATED	10-2009-7025052	5 / 12 / 2008		
0854 MA	PTL005010MA	MOROCCO	[4-6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS, AND METHODS RELATED	PV/32376	5 / 12 / 2008	31397	5 / 13 / 2010
0854 MX	PTL005010MX	MEXICO	[4-6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS, AND METHODS RELATED	MX/a/2009/011836	5 / 12 / 2008		
0854 MY	PTL005010MY	MALAYSIA	[4-6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS, AND METHODS RELATED	PI20094558	5 / 12 / 2008		
0854 NZ	PTL005010NZ	NEW ZEALAND	[4-6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS, AND METHODS RELATED	581325	5 / 12 / 2008		
0854 WO	PTL005010PC	WIPO	[4-6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS, AND METHODS RELATED	PCT/US2008/062584	5 / 12 / 2008		
0854 PH	PTL005010PH	PHILIPPINES	[4-6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS, AND METHODS RELATED	1-2009-502067	5 / 12 / 2008		
0854 SG	PTL005010SG	SINGAPORE	[4-6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS, AND METHODS RELATED	200907090-5	5 / 12 / 2008		

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0854 TN	PTL005010TN	TUNISIA	[4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS, AND METHODS RELATED	TN2009/0452	5/2/2008		
0854 US	PTL005010US	UNITED STATES	[4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS, AND METHODS RELATED	12/114,742	5/2/2008		
0854 ZA	PTL005010ZA	SOUTH AFRICA	[4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-(4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS, AND METHODS RELATED	2009/07493	5/2/2008	2009/07493	7/28/2010
0854 AR X1	PTL005011AR	ARGENTINA	[4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO	P090104261	11/4/2009		
0854 AU X1	PTL005011AU	AUSTRALIA	[4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO	2009313565	11/4/2009		
0854 BR X1	PTL005011BR	BRAZIL	[4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO	P10921649-9	11/4/2009		
0854 CA X1	PTL005011CA	CANADA	[4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO	2742601	11/4/2009		

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0854 CL X1	PTL005011CL	CHILE	[4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-14-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO	2040/2009	11/5 /2009		
0854 CN X1	PTL005011CN	CHINA	[4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO	200980153636.7	11/4 /2009		
0854 EP X1	PTL005011EP	EUROPEAN PATENT CONVENT	[4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-14-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO	09744901.1	11/4 /2009		
0854 GC X1	PTL005011GC	GULF COOPERATION	[4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO	GCC/P/2009/14633	11/4 /2009		
0854 HK X1	PTL005011HK	HONG KONG	[4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO	12101812.0	11/4 /2009		
0854 IN X1	PTL005011IN	INDIA	[4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO	3322DELNP/2011	11/4 /2009		

PATENT

REEL: 060800 FRAME: 0291

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0854 IQ X1	PTL005011IQ	IRAQ	[4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-[4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO	281/2009	10/22/2009		
0854 JO X1	PTL005011JO	JORDAN	[4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO	402/2009	11/2 /2009		
0854 JP X1	PTL005011JP	JAPAN	[4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO	2011-535655	11/4 /2009		
0854 KR X1	PTL005011KR	SOUTH KOREA	[4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-[4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO	10-2011-7012777	11/4 /2009		
0854 LB X1	PTL005011LB	LEBANON	[4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO	8808	11/4 /2009		
0854 MX X1	PTL005011MX	MEXICO	[4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO	MX/a/2011/004841	11/4 /2009		

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0854 WO X1	PTL005011PC	WIPO	[4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO	PCT/US2009/063313	11/4 /2009		
0854 PK X1	PTL005011PK	PAKISTAN	[4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO	982/2009	11/2 /2009		
0854 RU X1	PTL005011RU	RUSSIA	[4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO	201 1122385	11/4 /2009		
0854 TH X1	PTL005011TH	THAILAND	[4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO	0901004926	11/4 /2009		
0854 TW X1	PTL005011TW	TAIWAN	[4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO	098137421	11/4 /2009		
0854 US X1	PTL005011US	UNITED STATES	[4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO	12/265, 699	11/5 /2008		

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0854 VE X1	PTL005011VE	VENEZUELA	[4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-14-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO	2004-09	11/5 /2009		
0854 US X1C1	PTL005012US	UNITED STATES	[4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-14-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO	13/166,763	6 /22/2011		
0854 VE X1D1	PTL005012VE	VENEZUELA	[4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-14-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO	2005-09	11/5 /2009		
0859 US P1	PTL005500US	UNITED STATES	TEST CARTRIDGES FOR FLOW ASSAYS AND METHODS FOR THEIR USE	61/122,634	12/15/2008		
0859 WO	PTL005510PC	WIPO	TEST CARTRIDGES FOR FLOW ASSAYS AND METHODS FOR THEIR USE	PCT/US2009/067742	12/11/2009		
0859 US	PTL005510US	UNITED STATES	TEST CARTRIDGES FOR FLOW ASSAYS AND METHODS FOR THEIR USE	13/139,714	6 /14/2011		
0860 US P1	PTL005600US	UNITED STATES	SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW PH AND METHODS OF USE THEREOF	61/115,008	11/14/2008		
0860 AR	PTL005610AR	ARGENTINA	SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW PH AND METHODS OF USE THEREOF	P090104410	11/13/2009		

PATENT

REEL: 060800 FRAME: 0294



SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTFOLIA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0860 AU	PTL005610AU	AUSTRALIA	SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW PH AND METHODS OF USE THEREOF	2009313867	11/13/2009		
0860 BR	PTL005610BR	BRAZIL	SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW PH AND METHODS OF USE THEREOF	P10921049-0	11/13/2009		
0860 CA	PTL005610CA	CANADA	SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW PH AND METHODS OF USE THEREOF	2743639	11/13/2009		
0860 CL	PTL005610CL	CHILE	SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW PH AND METHODS OF USE THEREOF	2073/2009	11/13/2009		
0860 CN	PTL005610CN	CHINA	SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW PH AND METHODS OF USE THEREOF	200980153682.7	11/13/2009		
0860 EP	PTL005610EP	EUROPEAN PATENT CONVENT	SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW PH AND METHODS OF USE THEREOF	09759842.9	11/13/2009		
0860 GC	PTL005610GC	GULF COOPERATION	SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW PH AND METHODS OF USE THEREOF	GCC/P/2009/14697	11/14/2009		
0860 IN	PTL005610IN	INDIA	SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW PH AND METHODS OF USE THEREOF	4161/DELNP/2011	11/13/2009		

PATENT

REEL: 060800 FRAME: 0295

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTFOLIA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0860 IQ	PTL005610IQ	IRAQ	SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW pH AND METHODS OF USE THEREOF	287/2009	11/15/2009		
0860 JO	PTL005610JO	JORDAN	SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW pH AND METHODS OF USE THEREOF	421/2009	11/12/2009		
0860 JP	PTL005610JP	JAPAN	SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW pH AND METHODS OF USE THEREOF	2011-536535	11/13/2009		
0860 KR	PTL005610KR	SOUTH KOREA	SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW pH AND METHODS OF USE THEREOF	10-2011-7013465	11/13/2009		
0860 LB	PTL005610LB	LEBANON	SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW pH AND METHODS OF USE THEREOF	8820	11/13/2009		
0860 MX	PTL005610MX	MEXICO	SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW pH AND METHODS OF USE THEREOF	MX/a/2011/005128	11/13/2009		
0860 WO	PTL005610PC	WIPO	SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW pH AND METHODS OF USE THEREOF	PCT/US2009/064495	11/13/2009		
0860 PK	PTL005610PK	PAKISTAN	SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW pH AND METHODS OF USE THEREOF	1013/2009	11/13/2009		

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0860 RU	PTL005610RU	RUSSIA	SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW PH AND METHODS OF USE THEREOF	2011123377	11/13/2009		
0860 TH	PTL005610TH	THAILAND	SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW PH AND METHODS OF USE THEREOF	0901005093	11/13/2009		
0860 TW	PTL005610TW	TAIWAN	SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW PH AND METHODS OF USE THEREOF	098138684	11/13/2009		
0860 US	PTL005610US	UNITED STATES	SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW PH AND METHODS OF USE THEREOF	12/618,511	11/13/2009		
0860 VE	PTL005610VE	VENEZUELA	SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW PH AND METHODS OF USE THEREOF	2065-09	11/13/2009		
0860 US C1	PTL005611US	UNITED STATES	SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW PH AND METHODS OF USE THEREOF	13/633,055	10/1/2012		
0860 VE D1	PTL005611VE	VENEZUELA	SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW PH AND METHODS OF USE THEREOF	2065-09	11/13/2009		
0861 US P1	PTL005700US	UNITED STATES	ANTIDOTE FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME IN COMBINATION WITH BLOOD COAGULATING AGENTS	61/114,948	11/14/2008		

PATENT

REEL: 060800 FRAME: 0297

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0861 AU	PTL005710AU	AUSTRALIA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME IN COMBINATION WITH BLOOD COAGULATING AGENTS	2009314153	11/11/2009	2009314153	1/7/2016
0861 CA	PTL005710CA	CANADA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME IN COMBINATION WITH BLOOD COAGULATING AGENTS	2743496	11/11/2009	2743496	3/27/2018
0861 CH	PTL005710CH	SWITZERLAND	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME IN COMBINATION WITH BLOOD COAGULATING AGENTS	09756209.4	11/11/2009	2364165	1/3/2018
0861 CN	PTL005710CN	CHINA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME IN COMBINATION WITH BLOOD COAGULATING AGENTS	200980154527.7	11/11/2009	ZL200980154527.7	2/18/2015
0861 DE	PTL005710DE	GERMANY	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME IN COMBINATION WITH BLOOD COAGULATING AGENTS	09756209.4	11/11/2009	2364165	1/3/2018
0861 EP	PTL005710EP	EUROPEAN PATENT CONVENT	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME IN COMBINATION WITH BLOOD COAGULATING AGENTS	09756209.4	11/11/2009	2364165	1/3/2018
0861 FR	PTL005710FR	FRANCE	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME IN COMBINATION WITH BLOOD COAGULATING AGENTS	09756209.4	11/11/2009	2364165	1/3/2018
0861 GB	PTL005710GB	UNITED KINGDOM	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME IN COMBINATION WITH BLOOD COAGULATING AGENTS	09756209.4	11/11/2009	2364165	1/3/2018
0861 HK	PTL005710HK	HONG KONG	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME IN COMBINATION WITH BLOOD COAGULATING AGENTS	12102042.0	11/11/2009	1161138	8/24/2018

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0861 IE	PTL005710IE	IRELAND	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME IN COMBINATION WITH BLOOD COAGULATING AGENTS	09756209.4	11/11/2009	2364165	1/3/2018
0861 IN	PTL005710IN	INDIA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME IN COMBINATION WITH BLOOD COAGULATING AGENTS	2216/KOLNP/2011	11/11/2009	316691	7/24/2019
0861 JP	PTL005710JP	JAPAN	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME IN COMBINATION WITH BLOOD COAGULATING AGENTS	2011-536446	11/11/2009	5709316	3/13/2015
0861 KR	PTL005710KR	SOUTH KOREA	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME IN COMBINATION WITH BLOOD COAGULATING AGENTS	10-2011-7013384	11/11/2009	10-1649770	8/12/2016
0861 MX	PTL005710MX	MEXICO	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME IN COMBINATION WITH BLOOD COAGULATING AGENTS	MX/a/2011/004907	11/11/2009	307602	3/1/2013
0861 NZ	PTL005710NZ	NEW ZEALAND	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME IN COMBINATION WITH BLOOD COAGULATING AGENTS	592837	11/11/2009	592837	1/29/2013
0861 WO	PTL005710PC	WIPO	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME IN COMBINATION WITH BLOOD COAGULATING AGENTS	PCT/US2009/064060	11/11/2009		
0861 SG	PTL005710SG	SINGAPORE	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME IN COMBINATION WITH BLOOD COAGULATING AGENTS	201103350-3	11/11/2009	171199	1/15/2014
0861 US	PTL005710US	UNITED STATES	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME IN COMBINATION WITH BLOOD COAGULATING AGENTS	12/616,735	11/11/2009	8,455,439	6/14/2013

SCHEDULE A  
Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0861 JP D1	PTL005711JP	JAPAN	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME IN COMBINATION WITH BLOOD COAGULATING AGENTS	2014-120262	11/11/2009		
0861 US D1	PTL005711US	UNITED STATES	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME IN COMBINATION WITH BLOOD COAGULATING AGENTS	13/874,313	4/30/2013		
0862 US P1	PTL005800US	UNITED STATES	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	61/164,886	3/30/2009		
0862 CH	PTL005810CH	SWITZERLAND	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	10723842.0	3/29/2010	2414517	9/21/2016
0862 DE	PTL005810DE	GERMANY	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	10723842.0	3/29/2010	2414517	9/21/2016
0862 EP	PTL005810EP	EUROPEAN PATENT CONVENT	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	10723842.0	3/29/2010	2414517	9/21/2016
0862 ES	PTL005810ES	SPAIN	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	10723842.0	3/29/2010	2414517	9/21/2016
0862 FR	PTL005810FR	FRANCE	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	10723842.0	3/29/2010	2414517	9/21/2016
0862 GB	PTL005810GB	UNITED KINGDOM	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	10723842.0	3/29/2010	2414517	9/21/2016
0862 HK	PTL005810HK	HONG KONG	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	12102845.9	3/29/2010	1162584	12/8/2017
0862 IE	PTL005810IE	IRELAND	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	10723842.0	3/29/2010	2414517	9/21/2016
0862 IT	PTL005810IT	ITALY	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	10723842.0	3/29/2010	2414517	9/21/2016
0862 WO	PTL005810PC	WIPO	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	PCT/US2010/029064	3/29/2010		
0862 PT	PTL005810PT	PORTUGAL	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	10723842.0	3/29/2010	2414517	9/21/2016

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0862 US	PTL005810US	UNITED STATES	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	12/749,217	3/29/2010	8,268,783	9/18/2012
0862 EP D1	PTL005811EP	EUROPEAN PATENT CONVENT	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16185553.1	3/29/2010	3121271	7/24/2019
0862 HK D1	PTL005811HK	HONG KONG	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	17107164.6	3/29/2010		
0862 US D1	PTL005811US	UNITED STATES	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	13/591,098	8/21/2012	9,109,046	8/18/2015
0862 EP D2	PTL005812EP	EUROPEAN PATENT CONVENT	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	19179764.6	3/29/2010		
0862 HK D2	PTL005812HK	HONG KONG	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	42020012685.2	3/29/2010		
0862 US D1C1	PTL005812US	UNITED STATES	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	14/790,305	7/2/2015	9,587,233	3/7/2017
0862 US D1C2	PTL005813US	UNITED STATES	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	15/435,086	2/16/2017	10,190,111	1/29/2019
0862 US D1C3	PTL005814US	UNITED STATES	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	16/250,870	1/17/2019		
0863 US P1	PTL005900US	UNITED STATES	INHIBITORS OF JAK	61/176,077	5/6/2009		
0863 US P2	PTL005901US	UNITED STATES	INHIBITORS OF JAK	61/256,239	10/29/2009		
0863 AR	PTL005910AR	ARGENTINA	INHIBITORS OF JAK	20100101558	5/6/2010		
0863 WO	PTL005910PC	WIPO	INHIBITORS OF JAK	PCT/US2010/033921	5/6/2010		
0863 PK	PTL005910PK	PAKISTAN	INHIBITORS OF JAK	385/2010	5/6/2010		
0863 TW	PTL005910TW	TAIWAN	INHIBITORS OF JAK	099114720	5/6/2010		
0863 US	PTL005910US	UNITED STATES	INHIBITORS OF JAK	12/775,358	5/6/2010	8,367,689	2/5/2013
0863 VE	PTL005910VE	VENEZUELA	INHIBITORS OF JAK	00780-2010	5/6/2010		
0863 US D1	PTL005911US	UNITED STATES	INHIBITORS OF JAK	13/717,569	12/17/2012	8,853,230	10/7/2014
0865-LI-MILL AR	PTL006110AR	ARGENTINA	METHODS OF SYNTHESIZING FACTOR XA INHIBITORS	P100104654	12/15/2010		
0865-LI-MILL CA	PTL006110CA	CANADA	METHODS OF SYNTHESIZING FACTOR XA INHIBITORS	2784904	12/15/2010	2784904	10/10/2017
0865-LI-MILL CH	PTL006110CH	SWITZERLAND	METHODS OF SYNTHESIZING FACTOR XA INHIBITORS	10801495.2	12/15/2010	2513058	11/9/2016
0865-LI-MILL CN	PTL006110CN	CHINA	METHODS OF SYNTHESIZING FACTOR XA INHIBITORS	201080064124.6	12/15/2010	ZL201080064124.6	11/25/2015

PATENT

REEL: 060800 FRAME: 0301

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0865-LI-MILL DE	PTL006110DE	GERMANY	METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS	10801495.2	12/15/2010	2513058	11/9 /2016
0865-LI-MILL EP	PTL006110EP	EUROPEAN PATENT CONVENT	METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS	10801495.2	12/15/2010	2513058	11/9 /2016
0865-LI-MILL ES	PTL006110ES	SPAIN	METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS	10801495.2	12/15/2010	2513058	11/9 /2016
0865-LI-MILL FR	PTL006110FR	FRANCE	METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS	10801495.2	12/15/2010	2513058	11/9 /2016
0865-LI-MILL GB	PTL006110GB	UNITED KINGDOM	METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS	10801495.2	12/15/2010	2513058	11/9 /2016
0865-LI-MILL HK	PTL006110HK	HONG KONG	CRYSTALLINE SALTS OF A FACTOR Xa INHIBITOR	13104618.9	12/15/2010	1177480	1 /19/2018
0865-LI-MILL IE	PTL006110IE	IRELAND	METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS	10801495.2	12/15/2010	2513058	11/9 /2016
0865-LI-MILL IN	PTL006110IN	INDIA	METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS	1749/KOLNP/2012	12/15/2010		
0865-LI-MILL IT	PTL006110IT	ITALY	METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS	10801495.2	12/15/2010	2513058	11/9 /2016
0865-LI-MILL JP	PTL006110JP	JAPAN	METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS	2012-544794	12/15/2010	5766204	6 /26/2015
0865-LI-MILL WO	PTL006110PC	WIPO	METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS	PCT/US2010/060572	12/15/2010		
0865-LI-MILL PT	PTL006110PT	PORTUGAL	METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS	10801495.2	12/15/2010	2513058	11/9 /2016
0865-LI-MILL TW	PTL006110TW	TAIWAN	METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS	099144090	12/15/2010		
0865-LI-MILL US	PTL006110US	UNITED STATES	METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS	12/969.371	12/15/2010	8,394,964	3 /12/2013
0865-LI-MILL VE	PTL006110VE	VENEZUELA	METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS	2010-001978	12/15/2010		
0865-LI-MILL CN D1	PTL006111CN	CHINA	METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS	201510052519.9	12/15/2010		
0865-LI-MILL JP D1	PTL006111JP	JAPAN	METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS	2014-260157	12/15/2010		
0865-LI-MILL US D1	PTL006111US	UNITED STATES	METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS	13/757,483	2 /1 /2013	8,987,463	3 /24/2015
0866 US P1	PTL006200US	UNITED STATES	UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR Xa INHIBITORS AND METHODS OF USING THE SAME	61/225,887	7 /15/2009		
0866 CA	PTL006210CA	CANADA	UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR Xa INHIBITORS AND METHODS OF USING THE SAME	2767858	7 /14/2010	2767858	2 /12/2019

PATENT

REEL: 060800 FRAME: 0302



SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0866 CH	PTL006210CH	SWITZERLAND	UNIT DOSE FORMULATION OF ANTIDOTE FOR FACTOR Xa INHIBITORS FOR USE IN PREVENTING BLEEDING	10737699.8	7/14/2010	2453910	8/31/2016
0866 CN	PTL006210CN	CHINA	UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR Xa INHIBITORS AND METHODS OF USING THE SAME	201080040105.X	7/14/2010	ZL201080040105.X	7/25/2017
0866 DE	PTL006210DE	GERMANY	UNIT DOSE FORMULATION OF ANTIDOTE FOR FACTOR Xa INHIBITORS FOR USE IN PREVENTING BLEEDING	10737699.8	7/14/2010	2453910	8/31/2016
0866 EP	PTL006210EP	EUROPEAN PATENT CONVENT	UNIT DOSE FORMULATION OF ANTIDOTE FOR FACTOR Xa INHIBITORS FOR USE IN PREVENTING BLEEDING	10737699.8	7/14/2010	2453910	8/31/2016
0866 ES	PTL006210ES	SPAIN	UNIT DOSE FORMULATION OF ANTIDOTE FOR FACTOR Xa INHIBITORS FOR USE IN PREVENTING BLEEDING	10737699.8	7/14/2010	2453910	8/31/2016
0866 FR	PTL006210FR	FRANCE	UNIT DOSE FORMULATION OF ANTIDOTE FOR FACTOR Xa INHIBITORS FOR USE IN PREVENTING BLEEDING	10737699.8	7/14/2010	2453910	8/31/2016
0866 GB	PTL006210GB	UNITED KINGDOM	UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR Xa INHIBITORS AND METHODS OF USING THE SAME	10737699.8	7/14/2010	2453910	8/31/2016
0866 HK	PTL006210HK	HONG KONG	UNIT DOSE FORMULATION OF ANTIDOTE FOR FACTOR Xa INHIBITORS FOR USE IN PREVENTING BLEEDING	12108191.6	7/14/2010	1167346	10/13/2017
0866 IE	PTL006210IE	IRELAND	UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR Xa INHIBITORS AND METHODS OF USING THE SAME	10737699.8	7/14/2010	2453910	8/31/2016
0866 IN	PTL006210IN	INDIA	UNIT DOSE FORMULATION OF ANTIDOTE FOR FACTOR Xa INHIBITORS FOR USE IN PREVENTING BLEEDING	89/MUMNP/2012	7/14/2010		
0866 IT	PTL006210IT	ITALY	UNIT DOSE FORMULATION OF ANTIDOTE FOR FACTOR Xa INHIBITORS FOR USE IN PREVENTING BLEEDING	10737699.8	7/14/2010	2453910	8/31/2016

PATENT

REEL: 060800 FRAME: 0303

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0866 JP	PTL006210JP	JAPAN	UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR Xa INHIBITORS AND METHODS OF USING THE SAME	2012-520756	7/14/2010	6163304	6/23/2017
0866 WO	PTL006210PC	WIPO	UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR Xa INHIBITORS AND METHODS OF USING THE SAME	PCT/US2010/042015	7/14/2010		
0866 PT	PTL006210PT	PORTUGAL	UNIT DOSE FORMULATION OF ANTIDOTE FOR FACTOR Xa INHIBITORS FOR USE IN PREVENTING BLEEDING	10737699.8	7/14/2010	2453910	8/31/2016
0866 US	PTL006210US	UNITED STATES	UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR Xa INHIBITORS AND METHODS OF USING THE SAME	12/836,536	7/14/2010	9,056,106	6/16/2015
0866 JP D1	PTL006211JP	JAPAN	UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR Xa INHIBITORS AND METHODS OF USING THE SAME	2015-158084	7/14/2010		
0866 US C1	PTL006211US	UNITED STATES	UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR Xa INHIBITORS AND METHODS OF USING THE SAME	14/320,199	6/30/2014		
0866 US C2	PTL006212US	UNITED STATES	UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR Xa INHIBITORS AND METHODS OF USING THE SAME	15/212,105	7/15/2016		
0866 US C3	PTL006213US	UNITED STATES	UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR Xa INHIBITORS AND METHODS OF USING THE SAME	15/833,520	12/6/2017	10,765,726	9/8/2020
0866 US C4	PTL006214US	UNITED STATES	UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR Xa INHIBITORS AND METHODS OF USING THE SAME	16/943,933	7/30/2020		
0867 US P1	PTL006300US	UNITED STATES	METHODS FOR DIAGNOSIS AND TREATMENT OF THROMBOTIC DISORDERS MEDIATED BY 2C19*2	61/224,839	7/10/2009		
0867 US P2	PTL006301US	UNITED STATES	METHODS FOR DIAGNOSIS AND TREATMENT OF THROMBOTIC DISORDERS MEDIATED BY 2C19*2	61/321,596	4/7/2010		

PATENT

REEL: 060800 FRAME: 0304

SCHEDULE A  
Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0867 WO	PTL006310PC	WIPO	METHODS FOR DIAGNOSIS AND TREATMENT OF THROMBOTIC DISORDERS MEDIATED BY CYP2C19*2	PCT/US2010/041749	7/12/2010		
0867 US	PTL006310US	UNITED STATES	METHODS FOR DIAGNOSIS AND TREATMENT OF THROMBOTIC DISORDERS MEDIATED BY CYP2C19*2	13/383,402	1/10/2012		
0871 US P1	PTL006800US	UNITED STATES	BENZAMIDES AND NICOTINAMIDES AS SYK AND JAK MODULATORS	61/256,238	10/29/2009		
0871 US P2	PTL006801US	UNITED STATES	BENZAMIDES AND NICOTINAMIDES AS JAK MODULATORS	61/409,030	11/1/2010		
0871 EP	PTL006810EP	EUROPEAN PATENT CONVENT	NICOTINAMIDES AS JAK KINASE MODULATORS	11784870.5	11/1/2011		
0871 HK	PTL006810HK	HONG KONG	NICOTINAMIDES AS JAK KINASE MODULATORS	14102336.3	11/1/2011		
0871 WO	PTL006810PC	WIPO	NICOTINAMIDES AS JAK KINASE MODULATORS	PCT/US2011/058838	11/1/2011		
0871 TW	PTL006810TW	TAIWAN	NICOTINAMIDES AS JAK KINASE MODULATORS	100139878	11/1/2011		
0871 US	PTL006810US	UNITED STATES	NICOTINAMIDES AS JAK KINASE MODULATORS	13/286,984	11/1/2011	9,102,625	8/11/2015
0871 EP D1	PTL006811EP	EUROPEAN PATENT CONVENT	NICOTINAMIDES AS JAK KINASE MODULATORS	15178350.3	11/1/2011		
0871 US C1	PTL006811US	UNITED STATES	NICOTINAMIDES AS JAK KINASE MODULATORS	14/754,389	6/29/2015		
0873 P1	PTL007000US	UNITED STATES	CRYSTALLINE POLYMORPHS OF A FACTOR XA INHIBITOR	61/454,396	3/18/2011		
0873 AR	PTL007010AR	ARGENTINA	CRYSTALLINE FORMS OF A FACTOR XA INHIBITOR	P110103159	8/30/2011		
0873 AU	PTL007010AU	AUSTRALIA	CRYSTALLINE FORMS OF A FACTOR XA INHIBITOR	2011295909	8/31/2011	2011295909	9/3/2015
0873 CA	PTL007010CA	CANADA	CRYSTALLINE FORMS OF A FACTOR XA INHIBITOR	2810004	8/31/2011	2810004	9/10/2019
0873 CH	PTL007010CH	SWITZERLAND	CRYSTALLINE FORMS OF A FACTOR XA INHIBITOR	11757467.3	8/31/2011	2611779	8/10/2016
0873 CN	PTL007010CN	CHINA	CRYSTALLINE FORMS OF A FACTOR XA INHIBITOR	201180052042.4	8/31/2011	ZL201180052042.4	4/27/2016
0873 DE	PTL007010DE	GERMANY	CRYSTALLINE FORMS OF A FACTOR XA INHIBITOR	11757467.3	8/31/2011	2611779	8/10/2016
0873 EP	PTL007010EP	EUROPEAN PATENT CONVENT	CRYSTALLINE FORMS OF A FACTOR XA INHIBITOR	11757467.3	8/31/2011	2611779	8/10/2016
0873 ES	PTL007010ES	SPAIN	CRYSTALLINE FORMS OF A FACTOR XA INHIBITOR	11757467.3	8/31/2011	2611779	8/10/2016

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0873 FR	PTL007010FR	FRANCE	CRYSTALLINE FORMS OF A FACTOR XA INHIBITOR	11757467.3	8/31/2011	2611779	8/10/2016
0873 GB	PTL007010GB	UNITED KINGDOM	FACTOR XA INHIBITOR	11757467.3	8/31/2011	2611779	8/10/2016
0873 HK	PTL007010HK	HONG KONG	CRYSTALLINE FORMS OF A FACTOR XA INHIBITOR	13113654.5	8/31/2011	1186181	9/8/2017
0873 IE	PTL007010IE	IRELAND	CRYSTALLINE FORMS OF A FACTOR XA INHIBITOR	11757467.3	8/31/2011	2611779	8/10/2016
0873 IL	PTL007010IL	ISRAEL	CRYSTALLINE FORMS OF A FACTOR XA INHIBITOR	224698	8/31/2011	224698	5/11/2017
0873 IN	PTL007010IN	INDIA	CRYSTALLINE FORMS OF A FACTOR XA INHIBITOR	482/KOLNP/2013	8/31/2011		
0873 IT	PTL007010IT	ITALY	CRYSTALLINE FORMS OF A FACTOR XA INHIBITOR	11757467.3	8/31/2011	2611779	8/10/2016
0873 JP	PTL007010JP	JAPAN	CRYSTALLINE FORMS OF A FACTOR XA INHIBITOR	2013-527286	8/31/2011		
0873 MO	PTL007010MO	MACAO	CRYSTALLINE FORMS OF A FACTOR XA INHIBITOR	J/002277	8/31/2011	J/002277	7/27/2016
0873 NZ	PTL007010NZ	NEW ZEALAND	CRYSTALLINE FORMS OF A FACTOR XA INHIBITOR	608442	8/31/2011	608442	7/28/2015
0873 WO	PTL007010PC	WIPO	CRYSTALLINE FORMS OF A FACTOR XA INHIBITOR	PCT/US2011/050057	8/31/2011		
0873 PK	PTL007010PK	PAKISTAN	CRYSTALLINE FORMS OF A FACTOR XA INHIBITOR	635/2011	8/29/2011		
0873 PT	PTL007010PT	PORTUGAL	CRYSTALLINE FORMS OF A FACTOR XA INHIBITOR	11757467.3	8/31/2011	2611779	8/10/2016
0873 TW	PTL007010TW	TAIWAN	CRYSTALLINE FORMS OF A FACTOR XA INHIBITOR	100131157	8/30/2011		
0873 US	PTL007010US	UNITED STATES	CRYSTALLINE FORMS OF A FACTOR XA INHIBITOR	13/223,023	8/31/2011	8,946,269	2/3/2015
0873 JP D1	PTL007011JP	JAPAN	CRYSTALLINE FORMS OF A FACTOR XA INHIBITOR	2015-187427	8/31/2011		
0873 US D1	PTL007011US	UNITED STATES	CRYSTALLINE FORMS OF A FACTOR XA INHIBITOR	14/580,018	12/22/2014		
0873 JP D2	PTL007012JP	JAPAN	CRYSTALLINE FORMS OF A FACTOR XA INHIBITOR	2017-221050	8/31/2011		
0873 JP D3	PTL007013JP	JAPAN	CRYSTALLINE FORMS OF A FACTOR XA INHIBITOR	2019-81907	8/31/2011		
0874 P1	PTL007100US	UNITED STATES	PHARMACEUTICAL COMPOSITION AND DOSAGE FORMS OF ELINOGREL AND METHODS OF USE THEREOF	61/294,385	1/12/2010		
0874 P2	PTL007101US	UNITED STATES	PHARMACEUTICAL COMPOSITION AND DOSAGE FORMS OF ELINOGREL AND METHODS OF USE THEREOF	61/329,709	4/30/2010		

PATENT

REEL: 060800 FRAME: 0306

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0874 P3	PTL007102US	UNITED STATES	PHARMACEUTICAL COMPOSITION AND DOSAGE FORMS OF ELINOGREL AND METHODS OF USE THEREOF	61/334,068	5/12/2010		
0874 EP	PTL007110EP	EUROPEAN PATENT CONVENT	PHARMACEUTICAL COMPOSITION AND DOSAGE FORMS OF ELINOGREL AND METHODS OF USE THEREOF	11703298.7	1/12/2011		
0874 HK	PTL007110HK	HONG KONG	PHARMACEUTICAL COMPOSITION AND DOSAGE FORMS OF ELINOGREL AND METHODS OF USE THEREOF	13105867.4	1/12/2011		
0874 WO	PTL007110PC	WIPO	PHARMACEUTICAL COMPOSITION AND DOSAGE FORMS OF ELINOGREL AND METHODS OF USE THEREOF	PCT/US2011/021029	1/12/2011		
0874 US	PTL007110US	UNITED STATES	PHARMACEUTICAL COMPOSITION AND DOSAGE FORMS OF ELINOGREL AND METHODS OF USE THEREOF	13/521,906	3/11/2013		
0875 P1	PTL007200US	UNITED STATES	PHARMACEUTICAL COMPOSITION AND DOSAGE FORMS OF ELINOGREL AND METHODS OF USE THEREOF	61/329,725	4/30/2010		
0875 WO	PTL007210PC	WIPO	PHARMACEUTICAL COMPOSITION AND DOSAGE FORMS OF ELINOGREL AND METHODS OF USE THEREOF	PCT/US2011/034861	5/12/2011		
0875 US	PTL007210US	UNITED STATES	PHARMACEUTICAL COMPOSITION AND DOSAGE FORMS OF ELINOGREL AND METHODS OF USE THEREOF	13/695,428	1/14/2013		
0878 US P1	PTL007500US	UNITED STATES	METHODS AND FORMULATIONS OF TREATING THROMBOSIS WITH A FACTOR XA INHIBITOR AND A P-GLYCOPROTEIN INHIBITOR	61/379,339	9/1/2010		
0878 US P2	PTL007501US	UNITED STATES	METHODS AND FORMULATIONS OF TREATING THROMBOSIS WITH A FACTOR XA INHIBITOR AND A P-GLYCOPROTEIN INHIBITOR	61/454,402	3/18/2011		
0878 AR	PTL007510AR	ARGENTINA	METHODS AND FORMULATIONS OF TREATING THROMBOSIS WITH A FACTOR XA INHIBITOR AND A P-GLYCOPROTEIN INHIBITOR	P110103158	8/30/2011		
0878 WO	PTL007510PC	WIPO	METHODS AND FORMULATIONS OF TREATING THROMBOSIS WITH A FACTOR XA INHIBITOR AND A P-GLYCOPROTEIN INHIBITOR	PCT/US2011/050058	8/31/2011		

PATENT

REEL: 060800 FRAME: 0307

SCHEDULE A  
Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0878 PK	PTL007510PK	PAKISTAN	METHODS AND FORMULATIONS OF TREATING THROMBOSIS WITH A FACTOR XA INHIBITOR AND A P-GLYCOPROTEIN INHIBITOR	634/2011	8/29/2011		
0878 TW	PTL007510TW	TAIWAN	METHODS AND FORMULATIONS OF TREATING THROMBOSIS WITH A FACTOR XA INHIBITOR AND A P-GLYCOPROTEIN INHIBITOR	100131151	8/30/2011		
0878 US	PTL007510US	UNITED STATES	METHODS AND FORMULATIONS OF TREATING THROMBOSIS WITH BETRIXABAN AND A P-GLYCOPROTEIN INHIBITOR	13/223,038	8/31/2011		
0878 US C1	PTL007511US	UNITED STATES	METHODS AND FORMULATIONS OF TREATING THROMBOSIS WITH BETRIXABAN AND A P-GLYCOPROTEIN INHIBITOR	14/078,415	11/12/2013		
0879 US P1	PTL007600US	UNITED STATES	PREVENTION AND TREATMENT OF THROMBOSIS IN MEDICALLY ILL PATIENTS	61/529,755	8/31/2011		
0879 WO	PTL007610PC	WIPO	PREVENTION AND TREATMENT OF THROMBOSIS IN MEDICALLY ILL PATIENTS	PCT/US2012/053102	8/30/2012		
0879 US	PTL007610US	UNITED STATES	PREVENTION AND TREATMENT OF THROMBOSIS IN MEDICALLY ILL PATIENTS	14/241,824	4/1/2015		
0879 US C1	PTL007611US	UNITED STATES	PREVENTION AND TREATMENT OF THROMBOSIS IN MEDICALLY ILL PATIENTS	15/456,133	3/10/2017		
0879 US C2	PTL007612US	UNITED STATES	PREVENTION AND TREATMENT OF THROMBOSIS IN MEDICALLY ILL PATIENTS	16/256,909	1/24/2019		
0882 P1	PTL007900US	UNITED STATES	PROCESS FOR MAKING RECOMBINANT ANTIDOTE TO FACTOR XA INHIBITOR	61/598,694	2/14/2012		
0882 CN	PTL007910CN	CHINA	PROCESS FOR MAKING RECOMBINANT ANTIDOTE TO FACTOR XA INHIBITOR	201380012568.9	2/13/2013		
0882 EP	PTL007910EP	EUROPEAN PATENT CONVENT	PROCESS FOR MAKING RECOMBINANT ANTIDOTE TO FACTOR XA INHIBITOR	13706859.9	2/13/2013		
0882 HK	PTL007910HK	HONG KONG	PROCESS FOR MAKING RECOMBINANT ANTIDOTE TO FACTOR XA INHIBITOR	15105733.4	2/13/2013		
0882 IL	PTL007910IL	ISRAEL	PROCESS FOR MAKING RECOMBINANT ANTIDOTE TO FACTOR XA INHIBITOR	234073	2/13/2013		

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0882 IN	PTL007910IN	INDIA	PROCESS FOR MAKING RECOMBINANT ANTIDOTE TO FACTOR XA INHIBITOR	1793KOLNP/2014	2 /1/3/2013		
0882 JP	PTL007910JP	JAPAN	PROCESS FOR MAKING RECOMBINANT ANTIDOTE TO FACTOR XA INHIBITOR	2014-557747	2 /1/3/2013		
0882 KR	PTL007910KR	SOUTH KOREA	PROCESS FOR MAKING RECOMBINANT ANTIDOTE TO FACTOR XA INHIBITOR	10-2014-7025409	2 /1/3/2013		
0882 WO	PTL007910PC	WIPO	PROCESS FOR MAKING RECOMBINANT ANTIDOTE TO FACTOR XA INHIBITOR	PCT/US2013/025985	2 /1/3/2013		
0882 US	PTL007910US	UNITED STATES	PROCESS FOR MAKING RECOMBINANT ANTIDOTE TO FACTOR XA INHIBITOR	13/766,652	2 /1/3/2013		
0882 US C1	PTL007911US	UNITED STATES	PROCESS FOR MAKING RECOMBINANT ANTIDOTE TO FACTOR XA INHIBITOR	14/745,901	6 /2/2/2015		
0882 US C2	PTL007912US	UNITED STATES	PROCESS FOR MAKING RECOMBINANT ANTIDOTE TO FACTOR XA INHIBITOR	15/391,020	12/27/2016		
0882 US C3	PTL007913US	UNITED STATES	PROCESS FOR MAKING RECOMBINANT ANTIDOTE TO FACTOR XA INHIBITOR	16/127,864	9 /1/1/2018		
0883 US P1	PTL008000US	UNITED STATES	MODULATION OF FACTOR XA INHIBITOR-MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIDOTE	61/599,821	2 /1/6/2012		
0883 US P2	PTL008001US	UNITED STATES	MODULATION OF FACTOR XA INHIBITOR-MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIDOTE	61/682,615	8 /1/3/2012		
0883 US P3	PTL008002US	UNITED STATES	MODULATION OF FACTOR XA INHIBITOR-MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIDOTE	61/734,269	12/6 /2012		
0883 US P4	PTL008003US	UNITED STATES	MODULATION OF FACTOR XA INHIBITOR-MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIDOTE	61/756,842	1 /25/2013		

PATENT

REEL: 060800 FRAME: 0309

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0883 US P5	PTL008004US	UNITED STATES	MODULATION OF FACTOR XA INHIBITOR-MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIIDOTE	61/759,571	2/1/2013		
0883 EP	PTL008010EP	EUROPEAN PATENT CONVENT	MODULATION OF FACTOR XA INHIBITOR MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIIDOTE	13709603.8	2/14/2013		
0883 HK	PTL008010HK	HONG KONG	MODULATION OF FACTOR XA INHIBITOR MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIIDOTE	15105739.8	2/14/2013		
0883 WO	PTL008010PC	WIPO	MODULATION OF FACTOR XA INHIBITOR MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIIDOTE	PCT/US2013/026212	2/14/2013		
0883 US	PTL008010US	UNITED STATES	MODULATION OF FACTOR XA INHIBITOR MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIIDOTE	14/378,440	8/13/2014		
0883 US C1	PTL008011US	UNITED STATES	MODULATION OF FACTOR XA INHIBITOR MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIIDOTE	15/902,886	2/22/2018		
0883 US C2	PTL008012US	UNITED STATES	MODULATION OF FACTOR XA INHIBITOR-MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIIDOTE	16/519,732	7/23/2019		
0887 US P1	PTL008400US	UNITED STATES	METHOD FOR PURIFICATION OF RECOMBINANT FACTOR XA DERIVATIVES	61/659,821	6/14/2012		
0887 AU	PTL008410AU	AUSTRALIA	METHOD FOR PURIFICATION OF RECOMBINANT FACTOR XA DERIVATIVES	2013274288	6/12/2013	2013274288	11/30/2017
0887 CA	PTL008410CA	CANADA	METHOD FOR PURIFICATION OF RECOMBINANT FACTOR XA DERIVATIVES	2,876,361	6/12/2013	2,876,361	6/30/2020
0887 CH	PTL008410CH	SWITZERLAND	METHOD FOR PURIFICATION OF RECOMBINANT FACTOR XA DERIVATIVES	13732317.6	6/12/2013	2861614	11/30/2016



SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0887 CN	PTL008410CN	CHINA	METHOD FOR PURIFICATION OF RECOMBINANT FACTOR XA DERIVATIVES	2013800033420.3	6/1/2/2013	ZL2013800033420.3	6/23/2017
0887 DE	PTL008410DE	GERMANY	METHOD FOR PURIFICATION OF RECOMBINANT FACTOR XA DERIVATIVES	13732317.6	6/1/2/2013	2861614	11/30/2016
0887 EP	PTL008410EP	EUROPEAN PATENT CONVENT	METHOD FOR PURIFICATION OF RECOMBINANT FACTOR XA DERIVATIVES	13732317.6	6/1/2/2013	2861614	11/30/2016
0887 ES	PTL008410ES	SPAIN	METHOD FOR PURIFICATION OF RECOMBINANT FACTOR XA DERIVATIVES	13732317.6	6/1/2/2013	2861614	11/30/2016
0887 FR	PTL008410FR	FRANCE	METHOD FOR PURIFICATION OF RECOMBINANT FACTOR XA DERIVATIVES	13732317.6	6/1/2/2013	2861614	11/30/2016
0887 GB	PTL008410GB	UNITED KINGDOM	METHOD FOR PURIFICATION OF RECOMBINANT FACTOR XA DERIVATIVES	13732317.6	6/1/2/2013	2861614	11/30/2016
0887 HK	PTL008410HK	HONG KONG	METHOD FOR PURIFICATION OF RECOMBINANT FACTOR XA DERIVATIVES	15110322.1	6/1/2/2013	1209760	11/10/2017
0887 IE	PTL008410IE	IRELAND	METHOD FOR PURIFICATION OF RECOMBINANT FACTOR XA DERIVATIVES	13732317.6	6/1/2/2013	2861614	11/30/2016
0887 IL	PTL008410IL	ISRAEL	METHOD FOR PURIFICATION OF RECOMBINANT FACTOR XA DERIVATIVES	235896	6/1/2/2013	235896	5/29/2019
0887 IN	PTL008410IN	INDIA	METHOD FOR PURIFICATION OF RECOMBINANT FACTOR XA DERIVATIVES	8694/CHEMP/2014	6/1/2/2013	333397	2/28/2020
0887 IT	PTL008410IT	ITALY	METHOD FOR PURIFICATION OF RECOMBINANT FACTOR XA DERIVATIVES	13732317.6	6/1/2/2013	2861614	11/30/2016
0887 JP	PTL008410JP	JAPAN	METHOD FOR PURIFICATION OF RECOMBINANT FACTOR XA DERIVATIVES	2015-517406	6/1/2/2013	6261093	12/22/2017
0887 KR	PTL008410KR	SOUTH KOREA	METHOD FOR PURIFICATION OF RECOMBINANT FACTOR XA DERIVATIVES	10-2014-7036450	6/1/2/2013	10-2100629	4/8/2020
0887 WO	PTL008410PC	WIPO	METHOD FOR PURIFICATION OF RECOMBINANT FACTOR XA DERIVATIVES	PCT/US2013/045496	6/1/2/2013		
0887 PT	PTL008410PT	PORTUGAL	METHOD FOR PURIFICATION OF RECOMBINANT FACTOR XA DERIVATIVES	13732317.6	6/1/2/2013	2861614	11/30/2016

PATENT

REEL: 060800 FRAME: 0311

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0887 SG	PTL008410SG	SINGAPORE	METHOD FOR PURIFICATION OF RECOMBINANT FACTOR XA DERIVATIVES	11201408028Y	6/1/2/2013	11201408028Y	4/1/9/2017
0887 US	PTL008410US	UNITED STATES	METHOD FOR PURIFICATION OF RECOMBINANT FACTOR XA DERIVATIVES	14/4/06.645	12/9/2014		
0887 ZA	PTL008410ZA	SOUTH AFRICA	METHOD FOR PURIFICATION OF RECOMBINANT FACTOR XA DERIVATIVES	2014/08921	6/1/2/2013	2014/08921	8/26/2020
0887 KR D1	PTL008411KR	SOUTH KOREA	METHOD FOR PURIFICATION OF RECOMBINANT FACTOR XA DERIVATIVES	10-2020-7010091	6/1/2/2013		
0888 US P1	PTL008500US	UNITED STATES	COMPOUNDS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH THROMBOSIS	61/682.639	8/1/3/2012		
0892 US P1	PTL009100US	UNITED STATES	PHARMACEUTICAL COMPOSITIONS, DOSAGE FORMS AND NEW FORMS OF THE COMPOUND OF FORMULA (I), AND METHODS OF USE THEREOF	61/4/19.567	12/3/2010		
0892 CN	PTL009110CN	CHINA	PHARMACEUTICAL COMPOSITIONS, DOSAGE FORMS AND NEW FORMS OF THE COMPOUND OF FORMULA (I), AND METHODS OF USE THEREOF	201180066359.3	12/5/2011	ZL201180066359.3	6/29/2016
0892 EP	PTL009110EP	EUROPEAN PATENT CONVENT	PHARMACEUTICAL COMPOSITIONS, DOSAGE FORMS AND NEW FORMS OF THE COMPOUND OF FORMULA (I), AND METHODS OF USE THEREOF	11794108.8	12/5/2011	2646434	5/1/5/2019
0892 HK	PTL009110HK	HONG KONG	PHARMACEUTICAL COMPOSITIONS, DOSAGE FORMS AND NEW FORMS OF THE COMPOUND OF FORMULA (I), AND METHODS OF USE THEREOF	14103185.3	12/5/2011		
0892 IN	PTL009110IN	INDIA	PHARMACEUTICAL COMPOSITIONS, DOSAGE FORMS AND NEW FORMS OF THE COMPOUND OF FORMULA (I), AND METHODS OF USE THEREOF	1858/KOLNP/2013	12/5/2011		
0892 JP	PTL009110JP	JAPAN	PHARMACEUTICAL COMPOSITIONS, DOSAGE FORMS AND NEW FORMS OF THE COMPOUND OF FORMULA (I), AND METHODS OF USE THEREOF	2013-541384	12/5/2011		

PATENT

REEL: 060800 FRAME: 0312

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0892 WJO	PTL009110PC	WIPO	PHARMACEUTICAL COMPOSITIONS, DOSAGE FORMS AND NEW FORMS OF THE COMPOUND OF FORMULA (I), AND METHODS OF USE THEREOF	PCT/EP2011/071821	12/5 /2011		
0892 US	PTL009110US	UNITED STATES	PHARMACEUTICAL COMPOSITIONS, DOSAGE FORMS AND NEW FORMS OF THE COMPOUND OF FORMULA (I), AND METHODS OF USE THEREOF	13/890.632	5 /30/2013	8,987,285	3 /24/2015
0892 JP D1	PTL009111JP	JAPAN	PHARMACEUTICAL COMPOSITIONS, DOSAGE FORMS AND NEW FORMS OF THE COMPOUND OF FORMULA (I), AND METHODS OF USE THEREOF	2015-222649	12/5 /2011		
0892 JP D2	PTL009112JP	JAPAN	PHARMACEUTICAL COMPOSITIONS, DOSAGE FORMS AND NEW FORMS OF THE COMPOUND OF FORMULA (I), AND METHODS OF USE THEREOF	2017-242767	12/5 /2011		
0894 US P1	PTL0093300US	UNITED STATES	COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES	61/746,544	12/27/2012		
0894 US	PTL009310US	UNITED STATES	COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES	13/630,372	3 /14/2013	9,200,268	12/1 /2015
0894 AU	PTL009320AU	AUSTRALIA	BETRIXABAN DERIVATIVES AND USE THEREOF AS AFFINITY SOLID SUPPORT FOR PURIFICATION OF SERINE PROTEASES	2013370215	12/27/2013	2013370215	7 /19/2018
0894 CA	PTL009320CA	CANADA	METHODS FOR PURIFICATION OF SERINE PROTEASES	2,886,512	12/27/2013		
0894 CH	PTL009320CH	SWITZERLAND	METHODS FOR PURIFICATION OF SERINE PROTEASES	13822069.4	12/27/2013	2938596	11/1 /2017
0894 DE	PTL009320DE	GERMANY	METHODS FOR PURIFICATION OF SERINE PROTEASES	13822069.4	12/27/2013	2938596	11/1 /2017
0894 EP	PTL009320EP	EUROPEAN PATENT CONVENT	METHODS FOR PURIFICATION OF SERINE PROTEASES	13822069.4	12/27/2013	2938596	11/1 /2017
0894 FR	PTL009320FR	FRANCE	METHODS FOR PURIFICATION OF SERINE PROTEASES	13822069.4	12/27/2013	2938596	11/1 /2017
0894 GB	PTL009320GB	UNITED KINGDOM	METHODS FOR PURIFICATION OF SERINE PROTEASES	13822069.4	12/27/2013	2938596	11/1 /2017
0894 HK	PTL009320HK	HONG KONG	METHODS FOR PURIFICATION OF SERINE PROTEASES	16104212.6	12/27/2013	1216252	9 /14/2018

PATENT

REEL: 060800 FRAME: 0313

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0894 IE	PTL009320IE	IRELAND	METHODS FOR PURIFICATION OF SERINE PROTEASES	13822069.4	12/27/2013	2938596	11/11/2017
0894 IL	PTL009320IL	ISRAEL	COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES	239208	12/27/2013	239208	11/11/2018
0894 NZ	PTL009320NZ	NEW ZEALAND	COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES	709541	12/27/2013	709541	4/30/2019
0894 WO	PTL009320PC	WIPO	COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES	PCT/US2013/078130	12/27/2013		
0894 SG	PTL009320SG	SINGAPORE	COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES	11201504339T	12/27/2013	11201504339T	9/15/2017
0894 US X1	PTL009320US	UNITED STATES	COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES	14/142.655	12/27/2013		
0894 ZA	PTL009320ZA	SOUTH AFRICA	METHODS FOR PURIFICATION OF SERINE PROTEASES	2015/05200	12/27/2013		
0894 EP D1	PTL009321EP	EUROPEAN PATENT CONVENT	METHODS FOR PURIFICATION OF SERINE PROTEASES	17191911.1	12/27/2013		
0894 HK D1	PTL009321HK	HONG KONG	COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES	18111574.1	12/27/2013		
0894 US X1C1	PTL009321US	UNITED STATES	COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES	14/723.395	5/27/2015	9,644,195	5/9/2017
0894 ZA D1	PTL009321ZA	SOUTH AFRICA	INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES	2018/00077	12/27/2013	2018/00077	8/28/2019
0895 US P1	PTL009400US	UNITED STATES	INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES	61/756.359	1/24/2013		
0895 AU	PTL009410AU	AUSTRALIA	INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES	2013375294	3/13/2013	2013375294	11/22/2018
0895 CA	PTL009410CA	CANADA	INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES	2898975	3/13/2013		
0895 CH	PTL009410CH	SWITZERLAND	INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES	13712086.1	3/13/2013	2948168	7/18/2018
0895 CN	PTL009410CN	CHINA	INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES	201380073398.5	3/13/2013		

SCHEDULE A  
Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0895 DE	PTL009410DE	GERMANY	INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES	13712086.1	3/13/2013	2948168	7/18/2018
0895 EP	PTL009410EP	EUROPEAN PATENT CONVENT	INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES	13712086.1	3/13/2013	2948168	7/18/2018
0895 FR	PTL009410FR	FRANCE	INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES	13712086.1	3/13/2013	2948168	7/18/2018
0895 GB	PTL009410GB	UNITED KINGDOM	INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES	13712086.1	3/13/2013	2948168	7/18/2018
0895 HK	PTL009410HK	HONG KONG	INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES	16105784.1	3/13/2013	1217657	6/14/2019
0895 IE	PTL009410IE	IRELAND	INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES	13712086.1	3/13/2013	2948168	7/18/2018
0895 IL	PTL009410IL	ISRAEL	INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES	240063	3/13/2013	240063	7/11/2020
0895 NZ	PTL009410NZ	NEW ZEALAND	INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES	710975	3/13/2013		
0895 WO	PTL009410PC	WIPO	INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES	PCT/US2013/030927	3/13/2013		
0895 SG	PTL009410SG	SINGAPORE	INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES	11201505627R	3/13/2013		
0895 US	PTL009410US	UNITED STATES	INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES	147762,098	7/20/2015		
0895 ZA	PTL009410ZA	SOUTH AFRICA	INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES	2015/06033	3/13/2013		
0895 NZ D1	PTL009411NZ	NEW ZEALAND	INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES	727326	3/13/2013		
0895 SG D1	PTL009411SG	SINGAPORE	INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES	10201705189X	3/13/2013		
0895 US C1	PTL009411US	UNITED STATES	INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES	5/919,014	3/12/2018		
0896 US P1	PTL009500US	UNITED STATES	PYRIDAZINE COMPOUNDS AS JAK INHIBITORS	61/939,859	2/14/2014		

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0896 WO	PTL009810PC	WIPO	PYRIDAZINE COMPOUNDS AS JAK INHIBITORS	PCT/US2015/015687	2/12/2015		
0896 US	PTL009810US	UNITED STATES	PYRIDAZINE COMPOUNDS AS JAK INHIBITORS	15/118,433	8/11/2016	9,834,548	12/5/2017
0897 US P1	PTL009600US	UNITED STATES	ANTIDOTES TO FACTOR XA INHIBITORS	62/008,323	6/5/2014		
0899 US P1	PTL009800US	UNITED STATES	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	62/039,809	8/20/2014		
0899 AT	PTL009810AT	AUSTRIA	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	15834421.8	8/20/2015	3182993	7/1/2020
0899 AU	PTL009810AU	AUSTRALIA	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	2015305413	8/20/2015		
0899 BE	PTL009810BE	BELGIUM	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	15834421.8	8/20/2015	3182993	7/1/2020
0899 CA	PTL009810CA	CANADA	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	2,961,739	8/20/2015		
0899 CH	PTL009810CH	SWITZERLAND	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	15834421.8	8/20/2015	3182993	7/1/2020
0899 CN	PTL009810CN	CHINA	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	201580048166.3	8/20/2015		
0899 DE	PTL009810DE	GERMANY	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	15834421.8	8/20/2015	3182993	7/1/2020
0899 DK	PTL009810DK	DENMARK	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	15834421.8	8/20/2015	3182993	7/1/2020
0899 EA	PTL009810EA	EURASIAN PATENT	AQUEOUS FORMULATIONS OF FACTOR XA (FXA) ANTIDOTES FOR PREVENTING OR REDUCING BLEEDING AND THEIR USE	201790415	8/20/2015		
0899 EP	PTL009810EP	EUROPEAN PATENT CONVENT	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	15834421.8	8/20/2015	3182993	7/1/2020
0899 ES	PTL009810ES	SPAIN	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	15834421.8	8/20/2015	3182993	7/1/2020
0899 FI	PTL009810FI	FINLAND	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	15834421.8	8/20/2015	3182993	7/1/2020
0899 FR	PTL009810FR	FRANCE	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	15834421.8	8/20/2015	3182993	7/1/2020
0899 GB	PTL009810GB	UNITED KINGDOM	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	15834421.8	8/20/2015	3182993	7/1/2020
0899 HK	PTL009810HK	HONG KONG	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	17113464.1	8/20/2015		
0899 IE	PTL009810IE	IRELAND	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	15834421.8	8/20/2015	3182993	7/1/2020
0899 IL	PTL009810IL	ISRAEL	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	250413	8/20/2015		
0899 IT	PTL009810IT	ITALY	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	15834421.8	8/20/2015	3182993	7/1/2020

PATENT

REEL: 060800 FRAME: 0316

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTFOLIA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0899 JP	PTL009810JP	JAPAN	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	2017-509739	8/20/2015	6742986	7/31/2020
0899 KR	PTL009810KR	SOUTH KOREA	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	10-2017-7007503	8/20/2015		
0899 LU	PTL009810LU	LUXEMBOURG	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	15834421.8	8/20/2015	3182993	7/1/2020
0899 MC	PTL009810MC	MONACO	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	15834421.8	8/20/2015	3182993	7/1/2020
0899 MT	PTL009810MT	MALTA	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	15834421.8	8/20/2015	3182993	7/1/2020
0899 NL	PTL009810NL	NETHERLANDS	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	15834421.8	8/20/2015	3182993	7/1/2020
0899 NZ	PTL009810NZ	NEW ZEALAND	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	729764	8/20/2015		
0899 WO	PTL009810PC	WIPO	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	PCT/US2015/046173	8/20/2015		
0899 SE	PTL009810SE	SWEDEN	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	15834421.8	8/20/2015	3182993	7/1/2020
0899 SG	PTL009810SG	SINGAPORE	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	11201701247R	8/20/2015		
0899 US	PTL009810US	UNITED STATES	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	15/136,810	4/22/2016		
0899 ZA	PTL009810ZA	SOUTH AFRICA	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	2017/01764	8/20/2015	2017/01764	10/28/2020
0899 EA D1	PTL009811EA	EURASIAN PATENT	AQUEOUS FORMULATIONS OF FACTOR XA (FXA) ANTIDOTES FOR PREVENTING OR REDUCING BLEEDING AND THEIR USE	202091385	8/20/2015		
0899 EP D1	PTL009811EP	EUROPEAN PATENT CONVENT	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	20170763.5	8/20/2015		
0899 IL D1	PTL009811IL	ISRAEL	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	276960	8/20/2015		
0899 JP D1	PTL009811JP	JAPAN	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	2019-165981	8/20/2015		
0899 NZ D1	PTL009811NZ	NEW ZEALAND	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	766076	8/20/2015		
0899 US C1	PTL009811US	UNITED STATES	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	15/820,265	11/21/2017		
0899 US C1D1	PTL009812US	UNITED STATES	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	16/895,443	6/8/2020		
0899 US C1D2	PTL009813US	UNITED STATES	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	16/895,448	6/8/2020		
0900 US P1	PTL009900US	UNITED STATES	DEUTERIUM-ENRICHED BETRIXABAN	62/077,720	11/10/2014		
0900 US P2	PTL009901US	UNITED STATES	DEUTERIUM-ENRICHED BETRIXABAN	62/259,298	11/24/2015		

PATENT

REEL: 060800 FRAME: 0317

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0900 WO	PTL009910PC	WIPO	ISOTOPICALLY ENRICHED BERTRIXABAN	PCT/US2016/063649	11/23/2016		
0901 US P1	PTL010000US	UNITED STATES	INTERACTION OF ANDEXANET ALFA, A UNIVERSAL ANTIDOTE FOR FXA INHIBITORS, WITH TISSUE FACTOR PATHWAY INHIBITOR, ENHANCES REVERSAL OF FXA INHIBITOR-INDUCED ANTICOAGULATION	62/111,422	2/3/2015		
0902 US P1	PTL010100US	UNITED STATES	ACTIVATION OF FACTOR X BY FACTOR IXA AND TREATMENT OF HEMOPHILIA	62/142,976	4/3/2015		
0902 WO	PTL010110PC	WIPO	ACTIVATION OF FACTOR X BY FACTOR IXA AND TREATMENT OF HEMOPHILIA	PCT/US2016/025935	4/4/2016		
0903 US P1	PTL010200US	UNITED STATES	REVERSAL OF ANTICOAGULATION ANTIDOTES TO FACTOR XA INHIBITORS	62/142,977	4/3/2015		
0905 US P1	PTL010400US	UNITED STATES	ANTIDOTES TO FACTOR XA INHIBITORS	62/174,113	6/1/2015		
0905 US P2	PTL010401US	UNITED STATES	ANTIDOTES TO FACTOR XA INHIBITORS	62/350,027	6/1/4/2016		
0905 US P3	PTL010402US	UNITED STATES	ANTIDOTES TO FACTOR XA INHIBITORS	62/520,394	6/1/5/2017		
0905 US P4	PTL010403US	UNITED STATES	ANTIDOTES TO FACTOR XA INHIBITORS	62/686,968	6/1/9/2018		
0905 WO	PTL010410PC	WIPO	ANTIDOTES TO FACTOR XA INHIBITORS	PCT/US2019/037726	6/1/8/2019		
0908 US P1	PTL010800US	UNITED STATES	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	62/299,369	2/24/2016		
0908 CN	PTL010810CN	CHINA	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	201780020349.3	2/24/2017		
0908 EP	PTL010810EP	EUROPEAN PATENT CONVENT	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	17757375.5	2/24/2017		
0908 HK	PTL010810HK	HONG KONG	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	19125125.5	2/24/2017		
0908 WO	PTL010810PC	WIPO	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	PCT/US2017/019502	2/24/2017		
0908 US	PTL010810US	UNITED STATES	LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE	16/078,596	8/21/2018		
0910 US P1	PTL011000US	UNITED STATES	PREPARATION OF FACTOR XA DERIVATIVES	62/351,841	6/17/2016		
0910 AE	PTL011010AE	UNITED ARAB EMR	PREPARATION OF FACTOR XA DERIVATIVES	P6001776/18	6/1/9/2017		
0910 AU	PTL011010AU	AUSTRALIA	PREPARATION OF FACTOR XA DERIVATIVES	2017283720	6/1/9/2017		
0910 BR	PTL011010BR	BRAZIL	PREPARATION OF FACTOR XA DERIVATIVES	1120180759643	6/1/9/2017		

PATENT

REEL: 060800 FRAME: 0318



SCHEDULE A  
Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0910 CA	PTL011010CA	CANADA	PREPARATION OF FACTOR XA DERIVATIVES	3027457	6/1/9/2017		
0910 CL	PTL011010CL	CHILE	DERIVATIVES	201803654	6/1/9/2017		
0910 CN	PTL011010CN	CHINA	PREPARATION OF FACTOR XA DERIVATIVES	201780041530.2	6/1/9/2017		
0910 CO	PTL011010CO	COLOMBIA	PREPARATION OF FACTOR XA DERIVATIVES	NC2019/0000120	6/1/9/2017		
0910 EA	PTL011010EA	EURASIAN PATENT	PREPARATION OF FACTOR XA DERIVATIVES	2019990052	6/1/9/2017		
0910 EP	PTL011010EP	EUROPEAN PATENT	PREPARATION OF FACTOR XA DERIVATIVES	17814267.5	6/1/9/2017		
0910 HK	PTL011010HK	HONG KONG	PREPARATION OF FACTOR XA DERIVATIVES	19130002.9	6/1/9/2017		
0910 IL	PTL011010IL	ISRAEL	PREPARATION OF FACTOR XA DERIVATIVES	263591	6/1/9/2017		
0910 IN	PTL011010IN	INDIA	PREPARATION OF FACTOR XA DERIVATIVES	201817047272	6/1/9/2017		
0910 JP	PTL011010JP	JAPAN	PREPARATION OF FACTOR XA DERIVATIVES	2018-565888	6/1/9/2017		
0910 KR	PTL011010KR	SOUTH KOREA	PREPARATION OF FACTOR XA DERIVATIVES	10-2019-7000840	6/1/9/2017		
0910 MX	PTL011010MX	MEXICO	PREPARATION OF FACTOR XA DERIVATIVES	MX/a/2018/015873	6/1/9/2017		
0910 MY	PTL011010MY	MALAYSIA	PREPARATION OF FACTOR XA DERIVATIVES	P/2018002570	6/1/9/2017		
0910 NZ	PTL011010NZ	NEW ZEALAND	PREPARATION OF FACTOR XA DERIVATIVES	749018	6/1/9/2017		
0910 WO	PTL011010PC	WIPO	PREPARATION OF FACTOR XA DERIVATIVES	PCT/US2017/038169	6/1/9/2017		
0910 PE	PTL011010PE	PERU	PREPARATION OF FACTOR XA DERIVATIVES	3241-2018	6/1/9/2017		
0910 PH	PTL011010PH	PHILIPPINES	PREPARATION OF FACTOR XA DERIVATIVES	1-2018-502614	6/1/9/2017		
0910 SA	PTL011010SA	SAUDI ARABIA	PREPARATION OF FACTOR XA DERIVATIVES	518400680	6/1/9/2017		
0910 SG	PTL011010SG	SINGAPORE	PREPARATION OF FACTOR XA DERIVATIVES	11201810915Q	6/1/9/2017		
0910 TH	PTL011010TH	THAILAND	PREPARATION OF FACTOR XA DERIVATIVES	1801007698	6/1/9/2017		
0910 US	PTL011010US	UNITED STATES	DERIVATIVES	15/626.813	6/1/9/2017	10,604,748	3/31/2020
0910 ZA	PTL011010ZA	SOUTH AFRICA	PREPARATION OF FACTOR XA DERIVATIVES	2018/08425	6/1/9/2017		
0910 CL D1	PTL011011CL	CHILE	PREPARATION OF FACTOR XA DERIVATIVES	202001733	6/1/9/2017		

SCHEDULE A

Assignment between Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Unlimited Company

ALEXION REF	PORTOLA REF	COUNTRY	TITLE	SERIAL NO	FILE DATE	PATENT NO	ISSUE DATE
0910 US C1	PTL011011US	UNITED STATES	PREPARATION OF FACTOR XA DERIVATIVES	16/740,001	1/10/2020		
0917 US P1	PTL011700US	UNITED STATES	METHODS OF PREVENTION AND TREATMENT OF THROMBOSIS	62/678,951	5/31/2018		
0917 US	PTL011710US	UNITED STATES	TREATMENT OF THROMBOSIS	16/427,209	5/30/2019		
0918 US P1	PTL011800US	UNITED STATES	METHODS OF PREVENTION AND TREATMENT OF THROMBOSIS	62/688,825	6/22/2018		
0918 US	PTL011810US	UNITED STATES	TREATMENT OF THROMBOSIS	16/449,113	6/21/2019		
0920 US P1	PTL012000US	UNITED STATES	IDENTIFYING RISK OF STROKE IN HOSPITALIZED ACUTE HEART FAILURE PATIENTS	62/730,493	9/12/2018		
0921 US P2	PTL012201US	UNITED STATES	METHODS FOR TREATING INTRACRANIAL HEMORRHAGE AND ASSESSING EFFICACY	62/802,645	2/7/2019		
0921 WO	PTL012210PC	WIPO	METHODS FOR TREATING INTRACRANIAL HEMORRHAGE AND ASSESSING EFFICACY	PCT/US2020/017165	2/7/2020		
0922 US P1	PTL012300US	UNITED STATES	COMPOSITIONS AND METHODS FOR PREPARING FACTOR XA AND DERIVATIVES	62/884,652	8/8/2019		
0922 US P2	PTL012301US	UNITED STATES	COMPOSITIONS AND METHODS FOR PREPARING FACTOR XA AND DERIVATIVES	62/990,885	3/17/2020		
0922 WO	PTL012310PC	WIPO	COMPOSITIONS AND METHODS FOR PREPARING FACTOR XA AND DERIVATIVES	PCT/US2020/045039	8/5/2020		
0924 US P1	PTL012500US	UNITED STATES	ZAP70 INHIBITORS FOR TREATING CONDITIONS AND DISEASES	63/031,492	5/28/2020		
0925 US P1	PTL012600US	UNITED STATES	DIAMINE INHIBITORS OF ZAP70 FOR TREATING CONDITIONS AND DISEASES	63/031,514	5/28/2020		
0926 US P1	PTL012700US	UNITED STATES	AMIDE INHIBITORS OF ZAP70 FOR TREATING CONDITIONS AND DISEASES	63/031,515	5/28/2020		
0927 US P1	PTL012800US	UNITED STATES	BICYCLIC INHIBITORS OF ZAP70 FOR TREATING CONDITIONS AND DISEASES	63/031,518	5/28/2020		
0929 US P1	PTL013000US	UNITED STATES	METHODS FOR TESTING ANDEXXAMET POTENCY	63/039,795	6/16/2020		

PATENT

REEL: 060800 FRAME: 0320

RECORDED: 07/21/2022